US20030206887A1
(en)
*
|
1992-05-14 |
2003-11-06 |
David Morrissey |
RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
|
US20030216335A1
(en)
*
|
2001-11-30 |
2003-11-20 |
Jennifer Lockridge |
Method and reagent for the modulation of female reproductive diseases and conditions
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
AUPP249298A0
(en)
|
1998-03-20 |
1998-04-23 |
Ag-Gene Australia Limited |
Synthetic genes and genetic constructs comprising same I
|
CA2487328A1
(fr)
|
1998-03-20 |
1999-09-30 |
Benitec Australia Ltd. |
Sirna pour controler l'expression genique
|
CA2361201A1
(fr)
*
|
1999-01-28 |
2000-08-03 |
Medical College Of Georgia Research Institute, Inc. |
Composition et methode destinees a l'attenuation in vivo et in vitro de l'expression genique utilisant de l'arn double brin
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
US7601494B2
(en)
|
1999-03-17 |
2009-10-13 |
The University Of North Carolina At Chapel Hill |
Method of screening candidate compounds for susceptibility to biliary excretion
|
US20070021979A1
(en)
*
|
1999-04-16 |
2007-01-25 |
Cosentino Daniel L |
Multiuser wellness parameter monitoring system
|
EP2363478B1
(fr)
*
|
1999-04-21 |
2019-07-24 |
Alnylam Pharmaceuticals, Inc. |
Procédés et compositions pour inhiber la fonction de séquences de polynucléotides
|
US6423885B1
(en)
|
1999-08-13 |
2002-07-23 |
Commonwealth Scientific And Industrial Research Organization (Csiro) |
Methods for obtaining modified phenotypes in plant cells
|
US7531718B2
(en)
|
1999-08-26 |
2009-05-12 |
Monsanto Technology, L.L.C. |
Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
|
US7067722B2
(en)
|
1999-08-26 |
2006-06-27 |
Monsanto Technology Llc |
Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
|
DE60037735T2
(de)
|
1999-08-26 |
2009-01-02 |
Calgene Llc, Davis |
Pflanzen mit veränderten mehrfachungesättigten fettsäuren
|
GB9925459D0
(en)
*
|
1999-10-27 |
1999-12-29 |
Plant Bioscience Ltd |
Gene silencing
|
GB9927444D0
(en)
*
|
1999-11-19 |
2000-01-19 |
Cancer Res Campaign Tech |
Inhibiting gene expression
|
DE10100586C1
(de)
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
DE10160151A1
(de)
*
|
2001-01-09 |
2003-06-26 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
|
US7829693B2
(en)
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
WO2003070918A2
(fr)
|
2002-02-20 |
2003-08-28 |
Ribozyme Pharmaceuticals, Incorporated |
Inhibition mediee par interference arn d'une expression genique faisant appel a des acides nucleiques interferants courts chimiquement modifies (sina)
|
WO2005041859A2
(fr)
|
2003-04-30 |
2005-05-12 |
Sirna Therapeutics, Inc. |
Conjugues et compositions
|
US7491805B2
(en)
|
2001-05-18 |
2009-02-17 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US8273866B2
(en)
|
2002-02-20 |
2012-09-25 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
|
US8202979B2
(en)
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
US7833992B2
(en)
|
2001-05-18 |
2010-11-16 |
Merck Sharpe & Dohme |
Conjugates and compositions for cellular delivery
|
US8202846B2
(en)
|
2000-03-16 |
2012-06-19 |
Cold Spring Harbor Laboratory |
Methods and compositions for RNA interference
|
JP2003526367A
(ja)
|
2000-03-16 |
2003-09-09 |
ジェネティカ インコーポレイテッド |
Rna干渉の方法とrna干渉組成物
|
BRPI0117340B1
(pt)
*
|
2000-03-30 |
2016-10-18 |
Massachusetts Inst Technology |
método para examinar a função de um gene em uma célula in vitro
|
ATE450621T2
(de)
*
|
2000-03-30 |
2009-12-15 |
Whitehead Biomedical Inst |
Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
|
US20080032942A1
(en)
|
2000-08-30 |
2008-02-07 |
Mcswiggen James |
RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
|
US20030190635A1
(en)
*
|
2002-02-20 |
2003-10-09 |
Mcswiggen James A. |
RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
|
WO2005003350A2
(fr)
*
|
2003-06-27 |
2005-01-13 |
Sirna Therapeutics, Inc. |
Traitement medie par interference d'arn de la maladie d'alzheimer a l'aide d'acide nucleique interferent court (sina)
|
CA2427347C
(fr)
*
|
2000-10-31 |
2011-01-18 |
Commonwealth Scientific And Industrial Research Organisation |
Procede et moyens permettant de produire des plantes cerealieres resistantes au virus du nanisme jaune de l'orge
|
US20020173478A1
(en)
*
|
2000-11-14 |
2002-11-21 |
The Trustees Of The University Of Pennsylvania |
Post-transcriptional gene silencing by RNAi in mammalian cells
|
ES2728168T3
(es)
|
2000-12-01 |
2019-10-22 |
Max Planck Gesellschaft |
Moléculas pequeñas de ARN que median en la interferencia de ARN
|
WO2003035869A1
(fr)
*
|
2001-10-26 |
2003-05-01 |
Ribopharma Ag |
Utilisation d'un acide ribonucleique double brin pour inhiber de maniere ciblee l'expression d'un gene cible determine
|
DE10100587C1
(de)
*
|
2001-01-09 |
2002-11-21 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Zielgens
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
DE10100588A1
(de)
*
|
2001-01-09 |
2002-07-18 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Zielgens
|
US8546143B2
(en)
|
2001-01-09 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
US7423142B2
(en)
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
GB0104948D0
(en)
*
|
2001-02-28 |
2001-04-18 |
Novartis Res Foundation |
Novel methods
|
EP1386004A4
(fr)
|
2001-04-05 |
2005-02-16 |
Ribozyme Pharm Inc |
Modulation de l'expression genique associee a la proliferation inflammatoire et a la croissance de neurites, par des procedes faisant intervenir l'acide nucleique
|
US20050143333A1
(en)
*
|
2001-05-18 |
2005-06-30 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20050196765A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
|
EP3231445A1
(fr)
|
2001-05-18 |
2017-10-18 |
Sirna Therapeutics, Inc. |
Conjugués et compositions pour la fourniture cellulaire
|
WO2003070888A2
(fr)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc. |
Inhibition de l'expression du gene checkpoint kinase-1 (chk-1) mediee par l'arn i a l'aide d'un acide nucleique a interference proche
|
WO2003070887A2
(fr)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc. |
Inhibition mediee par interference d'arn de l'expression du gene de la proteine ezh2 du groupe polycomb a l'aide d'un acide nucleique court interferent (sina)
|
US20040198682A1
(en)
*
|
2001-11-30 |
2004-10-07 |
Mcswiggen James |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
|
CA2526831C
(fr)
*
|
2001-05-18 |
2012-07-31 |
Sirna Therapeutics, Inc. |
Interference arn a mediation assuree par l'inhibition de genes au moyen de petit acide nucleique interferent (ansi) modifie chimiquement
|
WO2003070969A2
(fr)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc. |
Inhibition de l'expression du gene bcl2 induite par interference arn au moyen de petits acides nucleiques interferents (sina)
|
WO2003070884A2
(fr)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc. |
Inhibition de l'expression du gene de la mdr p-glycoproteine induite par l'interference d'arn, au moyen d'acide nucleique interferant court (sina)
|
US20050182007A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20050288242A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
|
US20050159378A1
(en)
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
|
WO2005014811A2
(fr)
*
|
2003-08-08 |
2005-02-17 |
Sirna Therapeutics, Inc. |
Inhibition a mediation par interference arn de l'expression du gene xiap au moyen d'acide nucleique interferent court
|
US20040019001A1
(en)
*
|
2002-02-20 |
2004-01-29 |
Mcswiggen James A. |
RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
|
US20050176025A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
|
US20050233997A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
US20050148530A1
(en)
|
2002-02-20 |
2005-07-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050256068A1
(en)
|
2001-05-18 |
2005-11-17 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
|
US7109165B2
(en)
|
2001-05-18 |
2006-09-19 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US20050014172A1
(en)
|
2002-02-20 |
2005-01-20 |
Ivan Richards |
RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
|
US20050159381A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA)
|
US20050159382A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
|
US20050158735A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA)
|
US20050203040A1
(en)
*
|
2001-05-18 |
2005-09-15 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US20050196767A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
|
US20030175950A1
(en)
*
|
2001-05-29 |
2003-09-18 |
Mcswiggen James A. |
RNA interference mediated inhibition of HIV gene expression using short interfering RNA
|
US20050124566A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
|
WO2004097020A2
(fr)
*
|
2003-04-25 |
2004-11-11 |
Sirna Therapeutics, Inc. |
Inhibition induite par interference arn de l'expression genique d'une map kinase au moyen d'acide nucleique interferant court (sina)
|
WO2003070750A2
(fr)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc |
Inhibition de l'expression du gene du virus de l'hepatite c (vhc) induite par l'interference d'arn au moyen d'acide nucleique interferant court (sina)
|
US8008472B2
(en)
|
2001-05-29 |
2011-08-30 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
|
CA2921821A1
(fr)
|
2001-07-12 |
2003-01-23 |
University Of Massachusetts |
Production in vivo de petits arn d'interference qui regulent le silencage genique
|
US8022272B2
(en)
|
2001-07-13 |
2011-09-20 |
Sungene Gmbh & Co. Kgaa |
Expression cassettes for transgenic expression of nucleic acids
|
EP1432799A2
(fr)
*
|
2001-07-17 |
2004-06-30 |
Anne Josephine Milner |
Extinction d'expression genique par sirna
|
ES2386775T3
(es)
|
2001-07-23 |
2012-08-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Procedimientos y composiciones para la inhibición mediada por ARNi de la expresión génica en mamíferos
|
US10590418B2
(en)
|
2001-07-23 |
2020-03-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for RNAi mediated inhibition of gene expression in mammals
|
US7456335B2
(en)
*
|
2001-09-03 |
2008-11-25 |
Basf Plant Science Gmbh |
Nucleic acid sequences and their use in methods for achieving pathogen resistance in plants
|
DE10163098B4
(de)
*
|
2001-10-12 |
2005-06-02 |
Alnylam Europe Ag |
Verfahren zur Hemmung der Replikation von Viren
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
CN1604783A
(zh)
*
|
2001-10-26 |
2005-04-06 |
里伯药品公司 |
通过rna干扰治疗纤维化疾病的药物
|
DE10230996A1
(de)
*
|
2001-10-26 |
2003-07-17 |
Ribopharma Ag |
Medikament zur Behandlung eines Pankreaskarzinoms
|
CN1608133A
(zh)
*
|
2001-10-26 |
2005-04-20 |
里伯药品公司 |
双链核糖核酸用于治疗正(+)链rna病毒感染的用途
|
DE10202419A1
(de)
|
2002-01-22 |
2003-08-07 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
|
US20060009409A1
(en)
*
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
ATE443133T1
(de)
*
|
2002-02-01 |
2009-10-15 |
Life Technologies Corp |
Oligonukleotidzusammensetzungen mit verbesserter effizienz
|
EP1572902B1
(fr)
*
|
2002-02-01 |
2014-06-11 |
Life Technologies Corporation |
Courts fragments d'arn interferant haute activite visant a reduire l'expression de genes cibles
|
US7795422B2
(en)
|
2002-02-20 |
2010-09-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
|
US20090137510A1
(en)
*
|
2002-02-20 |
2009-05-28 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/ REL-A GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7928219B2
(en)
|
2002-02-20 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (SINA)
|
US7910724B2
(en)
|
2002-02-20 |
2011-03-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US7897753B2
(en)
|
2002-02-20 |
2011-03-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
|
US20090247613A1
(en)
*
|
2002-02-20 |
2009-10-01 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF B-CELL CLL/LYMPHOMA-2 (BCL2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7935812B2
(en)
|
2002-02-20 |
2011-05-03 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
|
US7928218B2
(en)
|
2002-02-20 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
|
EP1741781A3
(fr)
*
|
2002-02-20 |
2007-06-06 |
Sirna Therapeutics, Inc. |
Traitement de la maladie d'Alzheimer médié par l'interférence par l'ARN dans lequel il est fait appel à de petits fragments d'acides nucléiques interférants (siNA)
|
US8067575B2
(en)
|
2002-02-20 |
2011-11-29 |
Merck, Sharp & Dohme Corp. |
RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
|
AU2003210895A1
(en)
*
|
2002-02-20 |
2003-09-09 |
Ribozyme Pharmaceuticals, Inc. |
Rna interference mediated inhibition of cyclin d1 gene expression using short interfering nucleic acid (sina)
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
JP2005517450A
(ja)
*
|
2002-02-20 |
2005-06-16 |
サーナ・セラピューティクス・インコーポレイテッド |
短干渉核酸(siNA)を用いるRNA干渉媒介性標的発見および標的評価
|
US20090099117A1
(en)
|
2002-02-20 |
2009-04-16 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
AU2003220136A1
(en)
*
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7683165B2
(en)
|
2002-02-20 |
2010-03-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
|
US8013143B2
(en)
|
2002-02-20 |
2011-09-06 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
|
US8232383B2
(en)
*
|
2002-02-20 |
2012-07-31 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US7662952B2
(en)
|
2002-02-20 |
2010-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA)
|
US7678897B2
(en)
|
2002-02-20 |
2010-03-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
|
US20090192105A1
(en)
|
2002-02-20 |
2009-07-30 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA)
|
US7691999B2
(en)
|
2002-02-20 |
2010-04-06 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA)
|
US20090253774A1
(en)
|
2002-02-20 |
2009-10-08 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7683166B2
(en)
|
2002-02-20 |
2010-03-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
|
US7897757B2
(en)
|
2002-02-20 |
2011-03-01 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
|
US7667029B2
(en)
|
2002-02-20 |
2010-02-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
|
US7928220B2
(en)
|
2002-02-20 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
|
AU2003207708A1
(en)
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase genes
|
EP1478730A4
(fr)
*
|
2002-02-20 |
2006-01-25 |
Sirna Therapeutics Inc |
Inhibition, induite par arn d'interference, de l'expression genique de la superfamille tfn et de la superfamille des recepteurs de tfn a l'aide d'un acide nucleique a interference courte (sina)
|
US7700760B2
(en)
|
2002-02-20 |
2010-04-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
|
US7667030B2
(en)
|
2002-02-20 |
2010-02-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
US7893248B2
(en)
|
2002-02-20 |
2011-02-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
|
AU2003219833A1
(en)
*
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20090253773A1
(en)
|
2002-02-20 |
2009-10-08 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US8258288B2
(en)
|
2002-02-20 |
2012-09-04 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
|
EP1501853A4
(fr)
*
|
2002-02-20 |
2005-11-16 |
Sirna Therapeutics Inc |
Inhibition mediee par interference arn de l'expression genique d'un recepteur de facteur de croissance epidermique faisant appel a des acides nucleiques interferants courts
|
EP1710307A3
(fr)
*
|
2002-02-20 |
2007-06-06 |
Sirna Therapeutics, Inc. |
Interférence ARN permettant d'inhiber l'expression d'un gène à l'aide d'un acide nucléique interférant court (siNA)
|
US7897752B2
(en)
|
2002-02-20 |
2011-03-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA)
|
EP1484959A4
(fr)
|
2002-03-21 |
2005-08-31 |
Monsanto Technology Llc |
Constructions d'acides nucleiques et procedes de production de compositions d'huile de graines modifiees
|
US7166771B2
(en)
|
2002-06-21 |
2007-01-23 |
Monsanto Technology Llc |
Coordinated decrease and increase of gene expression of more than one gene using transgenic constructs
|
US7566813B2
(en)
|
2002-03-21 |
2009-07-28 |
Monsanto Technology, L.L.C. |
Nucleic acid constructs and methods for producing altered seed oil compositions
|
US8202845B2
(en)
|
2002-04-18 |
2012-06-19 |
Acuity Pharmaceuticals, Inc. |
Means and methods for the specific modulation of target genes in the CNS and the eye and methods for their identification
|
AU2003228667A1
(en)
*
|
2002-04-22 |
2003-12-19 |
Sirna Therapeutics Inc. |
Nucleic acid mediated disruption of hiv fusogenic peptide interactions
|
US20040180438A1
(en)
|
2002-04-26 |
2004-09-16 |
Pachuk Catherine J. |
Methods and compositions for silencing genes without inducing toxicity
|
JP2006506961A
(ja)
|
2002-05-23 |
2006-03-02 |
セプティア, インコーポレイテッド |
Rna干渉によるptp1bシグナル導入の調節
|
US20040248094A1
(en)
*
|
2002-06-12 |
2004-12-09 |
Ford Lance P. |
Methods and compositions relating to labeled RNA molecules that reduce gene expression
|
US20100075423A1
(en)
*
|
2002-06-12 |
2010-03-25 |
Life Technologies Corporation |
Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
|
WO2003106631A2
(fr)
*
|
2002-06-12 |
2003-12-24 |
Ambion, Inc. |
Procedes et compositions associes a des molecules d'arn marquees reduisant l'expression genique
|
US7655790B2
(en)
|
2002-07-12 |
2010-02-02 |
Sirna Therapeutics, Inc. |
Deprotection and purification of oligonucleotides and their derivatives
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
US7399851B2
(en)
|
2002-07-25 |
2008-07-15 |
Dana Farber Cancer Institute, Inc. |
Composition and method for imaging cells
|
CA2493364A1
(fr)
|
2002-07-26 |
2004-02-12 |
Basf Plant Science Gmbh |
Nouveaux procedes de selection
|
EP1389637B1
(fr)
*
|
2002-08-05 |
2012-05-30 |
Silence Therapeutics Aktiengesellschaft |
Molécules d'ARN interférant à bords francs
|
US20040241854A1
(en)
|
2002-08-05 |
2004-12-02 |
Davidson Beverly L. |
siRNA-mediated gene silencing
|
US20080274989A1
(en)
|
2002-08-05 |
2008-11-06 |
University Of Iowa Research Foundation |
Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
|
US20040023390A1
(en)
*
|
2002-08-05 |
2004-02-05 |
Davidson Beverly L. |
SiRNA-mediated gene silencing with viral vectors
|
US20050255086A1
(en)
*
|
2002-08-05 |
2005-11-17 |
Davidson Beverly L |
Nucleic acid silencing of Huntington's Disease gene
|
US20050042646A1
(en)
*
|
2002-08-05 |
2005-02-24 |
Davidson Beverly L. |
RNA interference suppresion of neurodegenerative diseases and methods of use thereof
|
IL166546A0
(en)
*
|
2002-08-05 |
2006-01-15 |
Atugen Ag |
Further novel forms of interfering ran molecules
|
US8729036B2
(en)
|
2002-08-07 |
2014-05-20 |
University Of Massachusetts |
Compositions for RNA interference and methods of use thereof
|
EP2278018A3
(fr)
|
2002-08-07 |
2012-01-04 |
BASF Plant Science GmbH |
Gènes codant des protéines associées au stress abiotique
|
US20040029275A1
(en)
*
|
2002-08-10 |
2004-02-12 |
David Brown |
Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
|
AU2003256615A1
(en)
|
2002-08-12 |
2004-02-25 |
New England Biolabs, Inc. |
Methods and compositions relating to gene silencing
|
ATE419865T1
(de)
|
2002-08-14 |
2009-01-15 |
Silence Therapeutics Ag |
Verwendung von protein-kinase-n-beta
|
EP1393742A1
(fr)
|
2002-08-14 |
2004-03-03 |
atugen AG |
Utilisation de la protéine kinase N bêta
|
US20060030534A1
(en)
|
2002-09-04 |
2006-02-09 |
Gabriele Dorn |
Treatment of neurological disorders by dsrna administration
|
US7956176B2
(en)
|
2002-09-05 |
2011-06-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20040053289A1
(en)
*
|
2002-09-09 |
2004-03-18 |
The Regents Of The University Of California |
Short interfering nucleic acid hybrids and methods thereof
|
US20040242518A1
(en)
*
|
2002-09-28 |
2004-12-02 |
Massachusetts Institute Of Technology |
Influenza therapeutic
|
AU2003300027A1
(en)
|
2002-10-10 |
2004-05-04 |
Wyeth |
Compositions, organisms and methodologies employing a novel human kinase
|
JP4820092B2
(ja)
|
2002-10-18 |
2011-11-24 |
サイレンス・セラピューティクス・アーゲー |
転移のための新規な因子及びその使用
|
WO2004038026A2
(fr)
|
2002-10-24 |
2004-05-06 |
Wyeth |
Compositions, organismes et procedes faisant appel a une nouvelle proteine phosphatase humaine
|
KR20120038546A
(ko)
|
2002-11-01 |
2012-04-23 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
HIF-1 알파의 siRNA 억제를 위한 조성물 및 방법
|
CA2504720C
(fr)
|
2002-11-05 |
2013-12-24 |
Isis Pharmaceuticals, Inc. |
Composes oligomere chimeres et leur utilisation dans la modulation genique
|
EP1562971B1
(fr)
|
2002-11-05 |
2014-02-12 |
Isis Pharmaceuticals, Inc. |
Composes oligomeres renfermant un substitut de sucre polycyclique et compositions intervenant dans la modulation genique
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
US9150606B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
CA2504929C
(fr)
|
2002-11-05 |
2014-07-22 |
Charles Allerson |
Compositions comprenant des nucleosides modifies en 2' de substitution destinees a la modulation de gene
|
AU2003287557A1
(en)
*
|
2002-11-07 |
2004-06-03 |
Lung-Ji Chang |
Modified dendritic cells
|
US9879266B2
(en)
|
2002-11-14 |
2018-01-30 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US9719092B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting CNTD2
|
US9771586B2
(en)
|
2002-11-14 |
2017-09-26 |
Thermo Fisher Scientific Inc. |
RNAi targeting ZNF205
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US9839649B2
(en)
|
2002-11-14 |
2017-12-12 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US10011836B2
(en)
|
2002-11-14 |
2018-07-03 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US9719094B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting SEC61G
|
WO2006006948A2
(fr)
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
Methodes et compositions permettant de selectionner des arnsi presentant une fonctionnalite amelioree
|
WO2004048933A2
(fr)
|
2002-11-21 |
2004-06-10 |
Wyeth |
Methodes de diagnostic de rcc et autres tumeurs solides
|
JP4526228B2
(ja)
*
|
2002-11-22 |
2010-08-18 |
隆 森田 |
RNAiによる新規治療法および治療剤
|
WO2004050831A2
(fr)
|
2002-11-27 |
2004-06-17 |
Wyeth |
Compositions, organismes et procedes faisant appel a une nouvelle kinase humaine
|
CA2513623A1
(fr)
|
2003-01-16 |
2004-08-05 |
The Trustees Of The University Of Pennsylvania |
Compositions et procedes destines a l'inhibition du gene icam-1 par arn a faible inhibition
|
WO2004074321A2
(fr)
|
2003-02-14 |
2004-09-02 |
Sagres Discovery, Inc. |
Nouveaux cibles therapeutiques du recepteur de couplage a la proteine g dans le cancer
|
DK2216407T3
(en)
|
2003-03-07 |
2016-03-29 |
Alnylam Pharmaceuticals Inc |
therapeutic compositions
|
US8653252B2
(en)
|
2003-03-21 |
2014-02-18 |
Santaris Pharma A/S |
Short interfering RNA (siRNA) analogues
|
AU2004229519B2
(en)
|
2003-04-09 |
2011-07-21 |
Alnylam Pharmaceuticals, Inc. |
iRNA conjugates
|
US20090298914A1
(en)
*
|
2003-04-15 |
2009-12-03 |
Sirna Therapeutics, Inc. |
RNA Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (SARS) Virus Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
WO2004092383A2
(fr)
*
|
2003-04-15 |
2004-10-28 |
Sirna Therapeutics, Inc. |
Inhibition par interference d'arn de l'expression genetique virale du syndrome respiratoire aigu severe au moyen d'acide nucleique d'interference court
|
AU2004232964B2
(en)
|
2003-04-17 |
2011-09-22 |
Alnylam Pharmaceuticals, Inc. |
Protected monomers
|
US7851615B2
(en)
|
2003-04-17 |
2010-12-14 |
Alnylam Pharmaceuticals, Inc. |
Lipophilic conjugated iRNA agents
|
US8017762B2
(en)
|
2003-04-17 |
2011-09-13 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
US7723509B2
(en)
|
2003-04-17 |
2010-05-25 |
Alnylam Pharmaceuticals |
IRNA agents with biocleavable tethers
|
ES2702942T3
(es)
|
2003-04-17 |
2019-03-06 |
Alnylam Pharmaceuticals Inc |
Agentes de ARNi modificados
|
US8796436B2
(en)
|
2003-04-17 |
2014-08-05 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
US7994305B2
(en)
|
2003-04-18 |
2011-08-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for siRNA inhibition of angiopoietin 1 and 2 and their receptor Tie2
|
AU2005212433B2
(en)
|
2003-05-23 |
2010-12-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sINA)
|
EP1633307A4
(fr)
*
|
2003-06-03 |
2009-06-24 |
Isis Pharmaceuticals Inc |
Modulation de l'expression de survivine
|
US7595306B2
(en)
|
2003-06-09 |
2009-09-29 |
Alnylam Pharmaceuticals Inc |
Method of treating neurodegenerative disease
|
US7786290B2
(en)
|
2003-06-13 |
2010-08-31 |
Alnylam Pharmaceuticals, Inc. |
Double-stranded ribonucleic acid with increased effectiveness in an organism
|
AU2004252559B2
(en)
*
|
2003-06-25 |
2010-07-29 |
Gencia Corporation |
Modified vectors for organelle transfection
|
WO2005007859A2
(fr)
*
|
2003-07-11 |
2005-01-27 |
Sirna Therapeutics, Inc. |
Inhibition par interference d'arn de l'expression genique de la carboxylase d'acetyl-coa au moyen d'un acide nucleique interferant court
|
BRPI0413118A
(pt)
|
2003-08-01 |
2006-10-03 |
Basf Plant Science Gmbh |
construção de ácido nucleico, vetor, célula hospedeira, processo para a produção de um polipeptìdeo, polipeptìdeo, anticorpo, tecido vegetal, material de propagação, material coletado ou uma planta, método para a avaliação de agonistas e antagonistas de uma atividade de um poliptìdeo codificado pela molécula de ácido nucleico, processo para a identificação de um composto que confere produção de produto quìmico fino aumentada em uma planta ou microorganismo, método para a identificação de um produto genético que confere um aumento na produção de produto quìmico fino em uma célula, método para a produção de uma composição agrìcola, composição, e, uso da molécula de ácido nucleico, do polipeptìdeo, ou da construção de ácido nucleico, ou do produto genético identificado
|
KR20060087531A
(ko)
|
2003-08-28 |
2006-08-02 |
노파르티스 아게 |
블런트-말단 및 3'-변형체를 갖는 간섭 rna 이중나선
|
US20070202505A1
(en)
*
|
2003-09-08 |
2007-08-30 |
Alex Chenchik |
Methods for gene function analysis
|
WO2005045037A2
(fr)
*
|
2003-10-23 |
2005-05-19 |
Sirna Therapeutics, Inc. |
Inhibition mediee par une interference arn de 5-alpha reductase et expression genique du recepteur d'androgenes faisant appel a un petit acide nucleique interferant (sina)
|
ATE503014T1
(de)
|
2003-11-04 |
2011-04-15 |
Geron Corp |
Rna-amidate und thioamidateur rnai
|
US8685946B2
(en)
*
|
2003-11-26 |
2014-04-01 |
Universiy of Massachusetts |
Sequence-specific inhibition of small RNA function
|
EP1704250B1
(fr)
|
2003-12-31 |
2012-09-19 |
The Penn State Research Foundation |
Procedes permettant de prevoir et de surmonter la resistance a la chimiotherapie dans le cancer de l'ovaire
|
EP1758998B1
(fr)
|
2004-01-30 |
2010-12-15 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotides et procedes d'utilisation de ceux-ci dans le traitement d'etats fibreux et d'autres maladies
|
WO2005073378A1
(fr)
*
|
2004-01-30 |
2005-08-11 |
Santaris Pharma A/S |
Arn a interference breve modifies (arnsi modifies)
|
US20090280567A1
(en)
*
|
2004-02-06 |
2009-11-12 |
Dharmacon, Inc. |
Stabilized sirnas as transfection controls and silencing reagents
|
DE602005017362D1
(de)
*
|
2004-02-06 |
2009-12-10 |
Dharmacon Inc |
Stabilisierte rnas als transfektionskontrollen und silencing-reagentien
|
US7655402B2
(en)
|
2004-02-06 |
2010-02-02 |
Wyeth Llc |
Diagnoses and therapeutics for cancer
|
US20060019914A1
(en)
|
2004-02-11 |
2006-01-26 |
University Of Tennessee Research Foundation |
Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes
|
US7781393B2
(en)
|
2004-02-25 |
2010-08-24 |
Dana-Farber Cancer Institute, Inc. |
Methods for inhibiting tumor cell growth
|
EP2636739B1
(fr)
|
2004-03-12 |
2014-12-10 |
Alnylam Pharmaceuticals Inc. |
Agents iRNA ciblant VEGF
|
KR101147147B1
(ko)
*
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
EP1734996B1
(fr)
|
2004-04-02 |
2013-05-22 |
The Regents of The University of California |
Compositions et methodes de traitement et de prevention d'une maladie associee a l'integrine alpha v beta 5
|
CA2557532A1
(fr)
|
2004-04-23 |
2005-11-10 |
Angela M. Christiano |
Inhibition d'un arnm associe a une proteine du gene hairless (sans poil)
|
DE102004025881A1
(de)
|
2004-05-19 |
2006-01-05 |
Beiersdorf Ag |
Oligoribonukleotide zur Beeinflussung des Haarwachstums
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
EP2471922A1
(fr)
|
2004-05-28 |
2012-07-04 |
Asuragen, Inc. |
Procédés et compositions impliquant du microARN
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
EP1602926A1
(fr)
|
2004-06-04 |
2005-12-07 |
University of Geneva |
Nouveaux moyens et méthodes pour le traitement de pertes d'audition ou l'audition fantôme
|
US20060003410A1
(en)
|
2004-06-10 |
2006-01-05 |
Lee-Ming Chuang |
Prostaglandin reductase
|
EP1758999B1
(fr)
|
2004-06-22 |
2011-03-09 |
The Board Of Trustees Of The University Of Illinois |
Procedes pour inhiber la proliferation des cellules tumorales avec foxm1 arnsi
|
AU2005259799A1
(en)
|
2004-07-02 |
2006-01-12 |
Protiva Biotherapeutics, Inc. |
Immunostimulatory siRNA molecules and uses therefor
|
WO2007087815A2
(fr)
|
2004-12-17 |
2007-08-09 |
Metanomics Gmbh |
Procédé de contrôle de production de produits chimiques fins
|
AU2005321630A1
(en)
|
2004-07-02 |
2006-07-06 |
Metanomics Gmbh |
Process for the production of fine chemicals
|
US7968762B2
(en)
|
2004-07-13 |
2011-06-28 |
Van Andel Research Institute |
Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
US20100132058A1
(en)
|
2004-07-23 |
2010-05-27 |
Diatchenko Luda B |
Methods and materials for determining pain sensitivity and predicting and treating related disorders
|
EP2166103B1
(fr)
|
2004-08-02 |
2013-05-22 |
BASF Plant Science GmbH |
Procédé d'isolation de séquence de terminaison de transcription
|
EP1789070B1
(fr)
|
2004-08-03 |
2012-10-24 |
Biogen Idec MA Inc. |
Influence du taj sur les fonctions neuronales
|
WO2006020768A2
(fr)
|
2004-08-10 |
2006-02-23 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides chimiquement modifies
|
WO2006023544A2
(fr)
|
2004-08-16 |
2006-03-02 |
Quark Biotech, Inc. |
Applications therapeutiques d'inhibiteurs de rtp801
|
WO2006017932A1
(fr)
|
2004-08-18 |
2006-02-23 |
Genesense Technologies Inc. |
Molecules de petit arn interferant dirigees contre la ribonucleotide reductase et ses utilisations
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
US20090170794A1
(en)
|
2004-09-10 |
2009-07-02 |
Somagenics Inc. |
Small interfering rnas that efficiently inhibit viral expression and methods of use thereof
|
AU2005286427B2
(en)
|
2004-09-24 |
2011-09-15 |
Basf Plant Science Gmbh |
Plant cells and plants with increased tolerance to environmental stress
|
WO2006035434A2
(fr)
|
2004-09-28 |
2006-04-06 |
Quark Biotech, Inc. |
Oligoribonucleotides et procedes d'utilisation associes pour le traitement de l'alopecie, des insuffisances renales aigues et d'autres maladies
|
EP2166098B1
(fr)
|
2004-10-05 |
2013-11-06 |
SunGene GmbH |
Cassettes d'expression constitutive pour la régulation de l'expression chez les plantes
|
WO2006044480A2
(fr)
|
2004-10-13 |
2006-04-27 |
University Of Georgia Research Foundation, Inc. |
Vegetaux transgeniques resistant aux nematodes
|
US9492400B2
(en)
|
2004-11-04 |
2016-11-15 |
Massachusetts Institute Of Technology |
Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
|
EP1655364A3
(fr)
|
2004-11-05 |
2006-08-02 |
BASF Plant Science GmbH |
Cassettes d'expression pour une expression préférentielle dans les graines.
|
ES2503743T3
(es)
|
2004-11-12 |
2014-10-07 |
Asuragen, Inc. |
Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
|
US7923207B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing pools
|
US7923206B2
(en)
*
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Method of determining a cellular response to a biological agent
|
US7935811B2
(en)
*
|
2004-11-22 |
2011-05-03 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing compositions
|
EP1662000B1
(fr)
|
2004-11-25 |
2011-03-30 |
SunGene GmbH |
Cassettes d'expression pour l'expression préférée dans des cellules stomatiques de plantes
|
EP1666599A3
(fr)
|
2004-12-04 |
2006-07-12 |
SunGene GmbH |
Cassettes d'expression pour l'expression préférée dans les cellules du mésophylle et/ou de l'épiderme de plantes
|
EP2072620B1
(fr)
|
2004-12-08 |
2013-05-08 |
SunGene GmbH |
Cassettes d'expression pour l'expression spécifique aux tissus vasculaires des plantes
|
EP1669456A3
(fr)
|
2004-12-11 |
2006-07-12 |
SunGene GmbH |
Cassettes d'expression pour l'expression preférentielle dans les méristèmes de plantes
|
US20060142228A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Ambion, Inc. |
Methods and compositions concerning siRNA's as mediators of RNA interference
|
TWI386225B
(zh)
|
2004-12-23 |
2013-02-21 |
Alcon Inc |
用於治療眼睛病症的結締組織生長因子(CTGF)RNA干擾(RNAi)抑制技術
|
PL1830888T3
(pl)
|
2004-12-27 |
2015-12-31 |
Silence Therapeutics Gmbh |
Kompleksy lipidowe pokryte PEG i ich wykorzystanie
|
CN101124339A
(zh)
*
|
2004-12-30 |
2008-02-13 |
托德·M·豪泽 |
使用自我保护寡核苷酸调节基因表达的组合物和方法
|
WO2006072887A1
(fr)
|
2005-01-05 |
2006-07-13 |
Eyegate Pharma Sa |
Dispositif d'iontophorese oculaire distribuant du petit arn interferent et des aptameres
|
DK1841793T3
(da)
|
2005-01-07 |
2010-07-19 |
Diadexus Inc |
Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse deraf
|
TW200639252A
(en)
|
2005-02-01 |
2006-11-16 |
Alcon Inc |
RNAi-mediated inhibition of ocular hypertension targets
|
CN103131697A
(zh)
|
2005-02-09 |
2013-06-05 |
巴斯福植物科学有限公司 |
在单子叶植物中调控表达的表达盒
|
EP1856264B1
(fr)
|
2005-02-26 |
2014-07-23 |
BASF Plant Science GmbH |
Cassettes d'expression destinees a une expression preferentielle de semences chez des plantes
|
JPWO2006093083A1
(ja)
|
2005-03-03 |
2008-08-07 |
和光純薬工業株式会社 |
架橋剤、架橋法、遺伝子発現調節法及び遺伝子機能調査法
|
EP2166100B1
(fr)
|
2005-03-08 |
2012-07-18 |
BASF Plant Science GmbH |
Séquences introniques facilitant l'expression
|
US7947660B2
(en)
|
2005-03-11 |
2011-05-24 |
Alcon, Inc. |
RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
|
US20060223777A1
(en)
*
|
2005-03-29 |
2006-10-05 |
Dharmacon, Inc. |
Highly functional short hairpin RNA
|
TWI335352B
(en)
|
2005-03-31 |
2011-01-01 |
Calando Pharmaceuticals Inc |
Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
|
JP2008535494A
(ja)
|
2005-04-07 |
2008-09-04 |
サグレシュ ディスカバリー, インコーポレイテッド |
癌関連遺伝子(prlr)
|
EP1865981A2
(fr)
|
2005-04-07 |
2007-12-19 |
Chiron Corporation |
Cacna1e dans le diagnostic, la detection et le traitement du cancer
|
JP4967137B2
(ja)
*
|
2005-04-18 |
2012-07-04 |
国立大学法人浜松医科大学 |
癌治療用組成物
|
WO2006113743A2
(fr)
*
|
2005-04-18 |
2006-10-26 |
Massachusetts Institute Of Technology |
Compositions et methodes servant a cibler arn vers l'expression de sialidase et leurs utilisations
|
EP1882037A2
(fr)
|
2005-05-10 |
2008-01-30 |
BASF Plant Science GmbH |
Cassettes d'expression pour l'expression préferentielle de semence dans des plantes
|
EP1888052A2
(fr)
|
2005-05-12 |
2008-02-20 |
Wisconsin Alumni Research Foundation |
Blocage de pin1 pour empecher le production de cytokines par les cellules immunitaires activees
|
FR2885808B1
(fr)
|
2005-05-19 |
2007-07-06 |
Oreal |
Vectorisation de dsrna par des particules cationiques et utilisation topique.
|
EP2159289A3
(fr)
|
2005-06-23 |
2010-03-24 |
BASF Plant Science GmbH |
Procédés améliorés pour la production de plants stablement transformés
|
US8703769B2
(en)
|
2005-07-15 |
2014-04-22 |
The University Of North Carolina At Chapel Hill |
Use of EGFR inhibitors to prevent or treat obesity
|
EP1764107A1
(fr)
*
|
2005-09-14 |
2007-03-21 |
Gunther Hartmann |
Compositions comportant les oligonucléotides d'ARN immunostimulatoire et les méthodes pour produire lesdits oligonucléotides d'ARN
|
WO2007039454A1
(fr)
|
2005-09-20 |
2007-04-12 |
Basf Plant Science Gmbh |
Methodes de regulation de l'expression genique utilisant ta-siarn
|
EP1934348B1
(fr)
|
2005-10-11 |
2018-05-02 |
Ben-Gurion University Of The Negev Research And Development Authority |
Compositions permettant d'effectuer un silençage de l'expression de vdac1 et des utilisations de celles-ci
|
US7320965B2
(en)
|
2005-10-28 |
2008-01-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Huntingtin gene
|
CN101346393B
(zh)
|
2005-11-02 |
2015-07-22 |
普洛体维生物治疗公司 |
修饰的siRNA分子及其应用
|
JP4929288B2
(ja)
|
2005-11-04 |
2012-05-09 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Nav1.8遺伝子の発現を抑制するための組成物および方法
|
US8362323B2
(en)
|
2005-11-08 |
2013-01-29 |
Basf Plant Science Gmbh |
Use of armadillo repeat (ARM1) polynucleotides for obtaining pathogen resistance in plants
|
WO2007056331A2
(fr)
|
2005-11-09 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions et procedes destines a inhiber l’expression de la mutation du gene du facteur v leiden
|
EP2468901B1
(fr)
|
2005-11-29 |
2017-04-05 |
Cambridge Enterprise Limited |
Marqueurs du cancer du sein
|
US9267937B2
(en)
|
2005-12-15 |
2016-02-23 |
Massachusetts Institute Of Technology |
System for screening particles
|
CN101395180B
(zh)
|
2005-12-30 |
2016-06-22 |
赢创罗姆有限责任公司 |
用作细胞穿膜肽的肽
|
EP2330202A3
(fr)
|
2006-01-06 |
2011-09-14 |
University Of Georgia Research Foundation, Inc. |
Plantes transgéniques résistantes aux nématodes de kystes
|
WO2007080143A1
(fr)
|
2006-01-12 |
2007-07-19 |
Basf Plant Science Gmbh |
Utilisation de polynucléotides de la stomatine (stm1) pour obtenir une résistance à un pathogène dans des végétaux
|
US7825099B2
(en)
|
2006-01-20 |
2010-11-02 |
Quark Pharmaceuticals, Inc. |
Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
|
DOP2007000015A
(es)
|
2006-01-20 |
2007-08-31 |
Quark Biotech Inc |
Usos terapéuticos de inhibidores de rtp801
|
US20090176977A1
(en)
*
|
2006-01-27 |
2009-07-09 |
Joacim Elmen |
Lna modified phosphorothiolated oligonucleotides
|
BRPI0707276B1
(pt)
|
2006-01-27 |
2021-08-31 |
Biogen Ma Inc |
Polipeptídeo de fusão antagonista de receptor nogo
|
CN101421406B
(zh)
|
2006-02-13 |
2016-08-31 |
孟山都技术有限公司 |
用于产生改变的种子油组成的核酸构建体和方法
|
US7910566B2
(en)
|
2006-03-09 |
2011-03-22 |
Quark Pharmaceuticals Inc. |
Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
|
DK2002004T3
(en)
|
2006-03-23 |
2015-11-30 |
Roche Innovation Ct Copenhagen As |
LITTLE INTERNAL SEGMENTED INTERFERENCE RNA
|
FR2898908A1
(fr)
|
2006-03-24 |
2007-09-28 |
Agronomique Inst Nat Rech |
Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence
|
US8968702B2
(en)
|
2006-03-30 |
2015-03-03 |
Duke University |
Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responses
|
EA014886B1
(ru)
|
2006-03-31 |
2011-02-28 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ ГЕНА Eg5
|
EP2090662A3
(fr)
|
2006-04-05 |
2012-10-31 |
Metanomics GmbH |
Procédé de production d'un produit chimique fin
|
JP2009541208A
(ja)
|
2006-04-13 |
2009-11-26 |
ノバルティス・バクシーンズ・アンド・ダイアグノスティクス・インコーポレイテッド |
がんを処置し、診断しもしくは検出する方法
|
US7691824B2
(en)
|
2006-04-28 |
2010-04-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the JC virus
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
EP3872179A1
(fr)
|
2006-05-11 |
2021-09-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions et procédés d'inhibition d'expression du gène pcsk9
|
US8367113B2
(en)
|
2006-05-15 |
2013-02-05 |
Massachusetts Institute Of Technology |
Polymers for functional particles
|
BRPI0712034A2
(pt)
|
2006-05-19 |
2012-01-10 |
Alnylam Pharmaceuticals Inc |
modulação de rnai de aha e usos terapêuticos do mesmo
|
EP2018443A4
(fr)
|
2006-05-22 |
2009-11-11 |
Alnylam Pharmaceuticals Inc |
Compositions et méthodes inhibant l'expression du gène ikk-b
|
WO2007141796A2
(fr)
|
2006-06-09 |
2007-12-13 |
Quark Pharmaceuticals, Inc. |
Utilisations thérapeutiques d'inhibiteurs de rtp801l
|
US7915399B2
(en)
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
US9381477B2
(en)
|
2006-06-23 |
2016-07-05 |
Massachusetts Institute Of Technology |
Microfluidic synthesis of organic nanoparticles
|
CA2657319C
(fr)
|
2006-07-11 |
2016-06-21 |
University Of Medicine And Dentistry Of New Jersey |
Compositions de mg53 et leur utilisation
|
KR101670085B1
(ko)
|
2006-07-21 |
2016-10-28 |
사일런스 테라퓨틱스 게엠베하 |
단백질 키나아제 3의 발현을 억제하기 위한 수단
|
US20100105610A1
(en)
|
2006-07-28 |
2010-04-29 |
Children's Memorial Hospital |
Methods of Inhibiting Tumor Cell Aggressiveness Using the Microenvironment of Human Embryonic Stem Cells
|
US7872118B2
(en)
|
2006-09-08 |
2011-01-18 |
Opko Ophthalmics, Llc |
siRNA and methods of manufacture
|
US7737266B2
(en)
|
2006-09-18 |
2010-06-15 |
Board Of Regents, The University Of Texas System |
RNAi modulation of SCAP and therapeutics uses thereof
|
US20090209478A1
(en)
|
2006-09-21 |
2009-08-20 |
Tomoko Nakayama |
Compositions and methods for inhibiting expression of the hamp gene
|
EP2081949B1
(fr)
*
|
2006-09-22 |
2014-12-10 |
GE Healthcare Dharmacon, Inc. |
Complexes d'oligonucléotides tripartites et procédés de silençage de gènes par interférence arn
|
JP2010507387A
(ja)
|
2006-10-25 |
2010-03-11 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
新規のsiRNAおよびその使用方法
|
US9279127B2
(en)
*
|
2006-11-01 |
2016-03-08 |
The Medical Research Fund At The Tel-Aviv Sourasky Medical Center |
Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression
|
US20080199475A1
(en)
|
2006-11-27 |
2008-08-21 |
Patrys Limited |
Novel glycosylated peptide target in neoplastic cells
|
CA2670696A1
(fr)
|
2006-11-27 |
2008-06-05 |
Diadexus, Inc. |
Compositions d'anticorps ovr110 et leurs procedes d'utilisation
|
EP2913341A1
(fr)
|
2006-12-22 |
2015-09-02 |
University of Utah Research Foundation |
Procédé de détection de maladies et d'états pathologiques oculaires et traitement de ceux-ci
|
CA2673361A1
(fr)
|
2007-01-15 |
2008-07-24 |
Basf Plant Science Gmbh |
Utilisation de polynucleotides de la subtilisine (rnr9) pour obtenir une resistance a un pathogene dans les plantes
|
CN101641010A
(zh)
|
2007-01-26 |
2010-02-03 |
路易斯维尔大学研究基金会公司 |
用作疫苗的外来体组分的修饰
|
US9217129B2
(en)
|
2007-02-09 |
2015-12-22 |
Massachusetts Institute Of Technology |
Oscillating cell culture bioreactor
|
CN101631868B
(zh)
|
2007-02-16 |
2016-02-10 |
巴斯福植物科学有限公司 |
用于在单子叶植物中调节胚特异性表达的核酸序列
|
JP2010518880A
(ja)
|
2007-02-26 |
2010-06-03 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
Rtp801のインヒビター及びその疾患の治療における使用
|
EP2474556A3
(fr)
|
2007-03-14 |
2012-10-17 |
Novartis AG |
Inhibiteurs APCDD1 pour traiter, diagnostiquer ou détecter le cancer
|
US7812002B2
(en)
|
2007-03-21 |
2010-10-12 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
|
US8796442B2
(en)
|
2007-03-21 |
2014-08-05 |
Brookhaven Science Associates, Llc. |
Combined hairpin-antisense compositions and methods for modulating expression
|
PE20090064A1
(es)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
AP2014007971A0
(en)
|
2007-03-29 |
2014-09-30 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expressionof a gene from the ebola
|
JP2010523595A
(ja)
|
2007-04-04 |
2010-07-15 |
マサチューセッツ インスティテュート オブ テクノロジー |
ポリ(アミノ酸)ターゲッティング部分
|
US8808747B2
(en)
|
2007-04-17 |
2014-08-19 |
Baxter International Inc. |
Nucleic acid microparticles for pulmonary delivery
|
WO2009014565A2
(fr)
|
2007-04-26 |
2009-01-29 |
Ludwig Institute For Cancer Research, Ltd. |
Procédés pour le diagnostic et le traitement des astrocytomes
|
EP2155860B1
(fr)
|
2007-05-03 |
2014-08-27 |
The Brigham and Women's Hospital, Inc. |
Cellules souches multipotentes et leurs utilisations
|
JP5296328B2
(ja)
|
2007-05-09 |
2013-09-25 |
独立行政法人理化学研究所 |
1本鎖環状rnaおよびその製造方法
|
DE112008001453T5
(de)
|
2007-05-22 |
2010-04-29 |
Basf Plant Science Gmbh |
Pflanzenzellen und Pflanzen mit erhöhter Toleranz und/oder Resistenz gegenüber Umweltstress und erhöhter Biomasseproduktion-KO
|
BRPI0811170B8
(pt)
|
2007-05-22 |
2021-05-25 |
Arcturus Therapeutics Inc |
oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila
|
US8097422B2
(en)
|
2007-06-20 |
2012-01-17 |
Salk Institute For Biological Studies |
Kir channel modulators
|
SI2170403T1
(sl)
|
2007-06-27 |
2014-07-31 |
Quark Pharmaceuticals, Inc. |
Sestavki in postopki za inhibicijo ekspresije pro-apoptotskih genov
|
BRPI0814189A2
(pt)
|
2007-07-05 |
2015-03-03 |
Novartis Ag |
Ácido ribonucleico de filamento duplo, composição farmacêutica e seus usos, método para inibir a expressão de fosfatidilinositol 4-cinase, vetor e uso de um composto que seletivamente inibe a atividade da fosfatidilinositol 4-cinase.
|
US9689031B2
(en)
|
2007-07-14 |
2017-06-27 |
Ionian Technologies, Inc. |
Nicking and extension amplification reaction for the exponential amplification of nucleic acids
|
WO2009012263A2
(fr)
|
2007-07-18 |
2009-01-22 |
The Trustees Of Columbia University In The City Of New York |
Micro-arn à spécificité cellulaire et compositions et utilisations de ces micro-arn
|
AU2008317495B2
(en)
|
2007-08-02 |
2013-08-01 |
Novimmune S.A. |
Anti-RANTES antibodies and methods of use thereof
|
JP2010536852A
(ja)
*
|
2007-08-23 |
2010-12-02 |
ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ |
シナプス形成の調節
|
WO2009033027A2
(fr)
|
2007-09-05 |
2009-03-12 |
Medtronic, Inc. |
Suppression de l'expression et/ou de la fonction du gène scn9a pour le traitement de la douleur
|
EP2198050A1
(fr)
|
2007-09-14 |
2010-06-23 |
Asuragen, INC. |
Microarn exprimés de manière différentielle dans le cancer du col de l'utérus et leurs utilisations
|
WO2009108217A2
(fr)
*
|
2007-09-18 |
2009-09-03 |
Intradigm Corporation |
Compositions comprenant un arnsi de k-ras et procédés d’utilisation
|
WO2009039300A2
(fr)
*
|
2007-09-18 |
2009-03-26 |
Intradigm Corporation |
Compositions comprenant du siarn hif-1 alpha et procédés pour les utiliser
|
EP2548962B1
(fr)
|
2007-09-19 |
2016-01-13 |
Applied Biosystems, LLC |
Formats de modification indépendants d'une séquence d'arnsi pour réduire des effets phénotypiques hors cible dans de l'arni, et formes stabilisées de ceux-ci
|
PL2644192T3
(pl)
|
2007-09-28 |
2017-09-29 |
Pfizer Inc. |
Ukierunkowanie na komórki nowotworowe z zastosowaniem nanocząstek
|
CN103898110A
(zh)
|
2007-10-03 |
2014-07-02 |
夸克制药公司 |
新siRNA结构
|
EP2630966B1
(fr)
|
2007-10-12 |
2017-04-19 |
Massachusetts Institute of Technology |
Nano-technologie de vaccin
|
US8097712B2
(en)
|
2007-11-07 |
2012-01-17 |
Beelogics Inc. |
Compositions for conferring tolerance to viral disease in social insects, and the use thereof
|
EP3141265A1
(fr)
|
2007-12-04 |
2017-03-15 |
Alnylam Pharmaceuticals, Inc. |
Conjugués glucidiques utilisés comme agents d'administration pour des oligonucléotides
|
US7871985B2
(en)
|
2007-12-10 |
2011-01-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor VII gene
|
US20100204305A1
(en)
*
|
2007-12-11 |
2010-08-12 |
Lorus Therapeutics Inc. |
Small interfering rna molecules against ribonucleotide reductase and uses thereof
|
US8614311B2
(en)
|
2007-12-12 |
2013-12-24 |
Quark Pharmaceuticals, Inc. |
RTP801L siRNA compounds and methods of use thereof
|
CA2708499A1
(fr)
*
|
2007-12-21 |
2009-07-02 |
Basf Plant Science Gmbh |
Plantes a rendement accru (ko nue)
|
WO2009090639A2
(fr)
*
|
2008-01-15 |
2009-07-23 |
Quark Pharmaceuticals, Inc. |
Composés d'arnsi et leurs utilisations
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
CN102016036B
(zh)
|
2008-02-11 |
2015-04-08 |
阿克赛医药公司 |
经修饰的RNAi多核苷酸及其用途
|
SG188121A1
(en)
|
2008-03-05 |
2013-03-28 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of eg5 and vegf genes
|
US20110105588A1
(en)
*
|
2008-03-12 |
2011-05-05 |
Intradigm Corporation |
Compositions comprising notch1 sirna and methods of use thereof
|
CA2720473A1
(fr)
|
2008-04-04 |
2009-10-08 |
Calando Pharmaceuticals, Inc. |
Compositions et utilisation d'inhibiteurs d'epas1
|
CA2721183C
(fr)
|
2008-04-11 |
2019-07-16 |
Alnylam Pharmaceuticals, Inc. |
Delivrance specifique a un site d'acides nucleiques en combinant des ligands de ciblage avec des composants endosomolytiques
|
US8278287B2
(en)
|
2008-04-15 |
2012-10-02 |
Quark Pharmaceuticals Inc. |
siRNA compounds for inhibiting NRF2
|
GB0807018D0
(en)
|
2008-04-17 |
2008-05-21 |
Fusion Antibodies Ltd |
Antibodies and treatment
|
WO2009137807A2
(fr)
|
2008-05-08 |
2009-11-12 |
Asuragen, Inc. |
Compositions et procédés liés à la modulation de miarn de néovascularisation ou d’angiogenèse
|
WO2009147684A2
(fr)
|
2008-06-06 |
2009-12-10 |
Quark Pharmaceuticals, Inc. |
Compositions et procédés pour le traitement de troubles de l'oreille
|
TWI455944B
(zh)
|
2008-07-01 |
2014-10-11 |
Daiichi Sankyo Co Ltd |
雙股多核苷酸
|
WO2010008582A2
(fr)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Système permettant d'administrer un médicament aux cellules phagocytaires
|
WO2010021720A1
(fr)
|
2008-08-19 |
2010-02-25 |
Nektar Therapeutics |
Conjugués d'acides nucléiques interférents courts
|
US8318693B2
(en)
|
2008-09-02 |
2012-11-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mutant EGFR gene
|
WO2011028218A1
(fr)
|
2009-09-02 |
2011-03-10 |
Alnylam Pharmaceuticals, Inc. |
Procédé pour la synthèse d'oligonucléotides triphosphates
|
EP2165710A1
(fr)
|
2008-09-19 |
2010-03-24 |
Institut Curie |
Récepteur TYRO3 de la tyrosine kinase en tant que cible thérapeutique dans le traitement d'une tumeur de la vessie
|
WO2010033247A2
(fr)
|
2008-09-22 |
2010-03-25 |
Rxi Pharmaceuticals Corporation |
Composés d'arni de taille réduite à auto-délivrance
|
WO2010039548A2
(fr)
|
2008-09-23 |
2010-04-08 |
Alnylam Pharmaceuticals, Inc. |
Modifications chimiques de monomères et d’oligonucléotides par cycloaddition
|
US8546554B2
(en)
|
2008-09-25 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
|
CA2738474C
(fr)
|
2008-09-29 |
2020-05-12 |
Monsanto Technology Llc |
Evenement transgenique de soja t mon87705 et procedes pour la detection de celui-ci
|
US8343497B2
(en)
|
2008-10-12 |
2013-01-01 |
The Brigham And Women's Hospital, Inc. |
Targeting of antigen presenting cells with immunonanotherapeutics
|
US8343498B2
(en)
|
2008-10-12 |
2013-01-01 |
Massachusetts Institute Of Technology |
Adjuvant incorporation in immunonanotherapeutics
|
US8277812B2
(en)
|
2008-10-12 |
2012-10-02 |
Massachusetts Institute Of Technology |
Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
|
US8591905B2
(en)
|
2008-10-12 |
2013-11-26 |
The Brigham And Women's Hospital, Inc. |
Nicotine immunonanotherapeutics
|
JP2012505657A
(ja)
*
|
2008-10-15 |
2012-03-08 |
ソマジェニックス インク. |
遺伝子発現の阻害のためのショートヘアピンrna
|
MX2011004268A
(es)
|
2008-10-20 |
2011-06-01 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion de transtiretina.
|
US9289475B2
(en)
|
2008-11-06 |
2016-03-22 |
The Johns Hopkins University |
Treatment of chronic inflammatory respiratory disorders
|
WO2010054379A2
(fr)
|
2008-11-10 |
2010-05-14 |
The United States Of America, As Represensted By The Secretary, Department Of Health And Human Services |
Signature génétique utilisée pour évaluer le pronostic chez des patients atteints de tumeurs solides
|
CA3039251C
(fr)
|
2008-11-10 |
2024-01-09 |
Arbutus Biopharma Corporation |
Nouveaux lipides et nouvelles compositions pour l'administration d'agents therapeutiques
|
WO2010059226A2
(fr)
|
2008-11-19 |
2010-05-27 |
Rxi Pharmaceuticals Corporation |
Inhibition de map4k4 via arni
|
WO2010065756A2
(fr)
|
2008-12-03 |
2010-06-10 |
Mdrna, Inc. |
Complexes d'arnsiu
|
EP2361306A1
(fr)
|
2008-12-04 |
2011-08-31 |
OPKO Ophthalmics, LLC |
Compositions et procédés pour l'inhibition sélective d'isoformes pro-angiogéniques de vegf
|
WO2010068816A1
(fr)
|
2008-12-10 |
2010-06-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arndb ciblé sur gnaq et procédés pour inhiber l'expression
|
EP2198879A1
(fr)
|
2008-12-11 |
2010-06-23 |
Institut Curie |
Agent modulateur de CD74 pour la régulation de la migration de cellules dendritiques et dispositif pour l'étude de la capacité de motilité d'une cellule
|
EP2370175A2
(fr)
|
2008-12-16 |
2011-10-05 |
Bristol-Myers Squibb Company |
Procédés d'inhibition de la prolifération de tumeurs quiescentes
|
WO2010080452A2
(fr)
|
2008-12-18 |
2010-07-15 |
Quark Pharmaceuticals, Inc. |
Composés d'arnsi et leurs procédés d'utilisation
|
EP2379076B1
(fr)
|
2008-12-23 |
2014-11-12 |
The Trustees of Columbia University in the City of New York |
Inhibiteurs de la phosphodiestérase et utilisations de ces derniers
|
WO2010074783A1
(fr)
|
2008-12-23 |
2010-07-01 |
The Trustees Of Columbia University In The City Of New York |
Inhibiteurs de la phosphodiestérase et utilisations de ces derniers
|
WO2010078536A1
(fr)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition de pcsk9 par arni
|
WO2010090762A1
(fr)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Duplexes d'arn avec régions de nucléotide phosphorothioate à brin unique pour fonctionnalité supplémentaire
|
US20110319476A1
(en)
*
|
2009-02-12 |
2011-12-29 |
Opko Curna, Llc |
Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
|
CN101525388B
(zh)
*
|
2009-02-20 |
2012-02-01 |
中国人民解放军第四军医大学 |
特异性双链rna结合蛋白嵌合体及其在病毒感染性疾病中的应用
|
WO2010099341A1
(fr)
|
2009-02-26 |
2010-09-02 |
Alnylam Pharmaceuticals, Inc. |
Composition et procédés d'inhibition de l'expression du gène mig-12
|
EP3424939A1
(fr)
|
2009-03-02 |
2019-01-09 |
Alnylam Pharmaceuticals Inc. |
Modifications chimiques d'acide nucléique
|
CA2754043A1
(fr)
|
2009-03-12 |
2010-09-16 |
Alnylam Pharmaceuticals, Inc. |
Compositions formulees de lipides et procedes d'inhibition de l'expression de genes de eg5 et de vegf
|
AU2010226604A1
(en)
|
2009-03-19 |
2011-10-13 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing
|
US20120029054A1
(en)
|
2009-03-19 |
2012-02-02 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
|
EP2408458A1
(fr)
|
2009-03-19 |
2012-01-25 |
Merck Sharp&Dohme Corp. |
INHIBITION INDUITE PAR ARN INTERFÉRENCE DE L'EXPRESSION DU GÈNE TRANSDUCTEUR DE SIGNAL ET ACTIVITATEUR DE TRANSCRIPTION 6 (STAT6) AU MOYEN D'UN ACIDE NUCLÉIQUE INTERFÉRENT COURT (ANsi)
|
US20120016011A1
(en)
|
2009-03-19 |
2012-01-19 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
CA2756069A1
(fr)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
Inhibition a mediation par l'interference arn de l'expression du gene de la molecule d'adhesion intercellulaire 1 (icam-1) faisant appel a de courts acides nucleiques interferents (ansi)
|
EP2411516A1
(fr)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
Inhibition par interférence arn de l'expression du gène kinase 1 de régulation du signal d'apoptose (ask1) au moyen d'un acide nucléique interférent court (ansi)
|
WO2010111468A2
(fr)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
INHIBITION PAR INTERFÉRENCE ARN DE L'EXPRESSION DU GÈNE DE LA CHAÎNE BÊTA DU FACTEUR DE CROISSANCE DES NERFS (NGFß) AU MOYEN D'UN ACIDE NUCLÉIQUE INTERFÉRENT COURT (ANSI)
|
JP2012521763A
(ja)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いたシグナル伝達性転写因子1(STAT1)遺伝子発現のRNA干渉媒介性阻害
|
WO2010111490A2
(fr)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
Inhibition à médiation par l'interférence arn de l'expression du gène de la lymphopoïétine stromale thymique (tslp) faisant appel à de courts acides nucléiques interférents (ansi)
|
US20100297127A1
(en)
|
2009-04-08 |
2010-11-25 |
Ghilardi Nico P |
Use of il-27 antagonists to treat lupus
|
US8283332B2
(en)
|
2009-04-17 |
2012-10-09 |
University Of Louisville Research Foundation, Inc. |
PFKFB4 inhibitors and methods of using the same
|
CA3020943A1
(fr)
|
2009-04-22 |
2010-10-28 |
Basf Plant Science Company Gmbh |
Promoteur specifique des graines entieres
|
US8822426B2
(en)
|
2009-05-05 |
2014-09-02 |
Beeologics Inc. |
Prevention and treatment of nosema disease in bees
|
ES2804764T3
(es)
|
2009-06-01 |
2021-02-09 |
Halo Bio Rnai Therapeutics Inc |
Polinucleótidos para la interferencia de ARN multivalente, composiciones y métodos de uso de los mismos
|
EP2258858A1
(fr)
|
2009-06-05 |
2010-12-08 |
Universitätsklinikum Freiburg |
Modèle animal pour le cancer transgénique pour LSD1
|
SG10201403054SA
(en)
|
2009-06-10 |
2014-10-30 |
Tekmira Pharmaceuticals Corp |
Improved lipid formulation
|
MX2011013421A
(es)
|
2009-06-15 |
2012-03-16 |
Alnylam Pharmaceuticals Inc |
Arnds formulado con lipido de direccionamiento del gen pcsk9.
|
EP2266550A1
(fr)
|
2009-06-15 |
2010-12-29 |
Institut Curie |
Antagonistes de bêta-caténine pour la prévention et/ou le traitement des troubles neuro-dégénératifs
|
US9051567B2
(en)
|
2009-06-15 |
2015-06-09 |
Tekmira Pharmaceuticals Corporation |
Methods for increasing efficacy of lipid formulated siRNA
|
WO2011003901A1
(fr)
|
2009-07-10 |
2011-01-13 |
Basf Plant Science Company Gmbh |
Cassettes d'expression pour l'expression spécifiquement dans l'endosperme dans des plantes
|
EP2454371B1
(fr)
|
2009-07-13 |
2021-01-20 |
Somagenics, Inc. |
Modification chimique de petits arn en épingle à cheveux pour l'inhibition d'une expression de gène
|
HUE026708T2
(en)
|
2009-07-14 |
2016-07-28 |
Mayo Foundation |
Peptide-mediated, non-covalent delivery of active substances in blood glucose
|
ES2629167T3
(es)
|
2009-07-20 |
2017-08-07 |
Bristol-Myers Squibb Company |
Combinación de anticuerpo anti-CTLA4 con etopósido para el tratamiento sinérgico de enfermedades proliferativas
|
CA2767409C
(fr)
|
2009-07-24 |
2018-10-30 |
The Regents Of The University Of California |
Procedes et compositions destines a traiter et a prevenir des maladies associees a l'integrine ?v?5
|
US20110039789A1
(en)
*
|
2009-08-14 |
2011-02-17 |
Institut Curie |
Use of Huntingtin Protein for the Diagnosis and the Treatment of Cancer
|
AP2015008874A0
(en)
|
2009-08-14 |
2015-11-30 |
Alnylam Pharmaceuticals Inc |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
WO2011035065A1
(fr)
|
2009-09-17 |
2011-03-24 |
Nektar Therapeutics |
Chitosanes monoconjugués en tant qu'agents de distribution pour de petits acides nucléiques interférents
|
US20150025122A1
(en)
|
2009-10-12 |
2015-01-22 |
Larry J. Smith |
Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
|
US8962584B2
(en)
|
2009-10-14 |
2015-02-24 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Compositions for controlling Varroa mites in bees
|
WO2011063409A1
(fr)
|
2009-11-23 |
2011-05-26 |
Aquabounty Technologies, Inc. |
Stérilité induite par la voie maternelle chez les animaux
|
TW201124160A
(en)
|
2009-11-26 |
2011-07-16 |
Quark Pharmaceuticals Inc |
SiRNA compounds comprising terminal substitutions
|
WO2011067712A1
(fr)
|
2009-12-03 |
2011-06-09 |
Basf Plant Science Company Gmbh |
Cassette d'expression pour expression spécifique de l'embryon dans des plantes
|
WO2011071916A2
(fr)
|
2009-12-07 |
2011-06-16 |
The Johns Hopkins University |
Sr-bi en tant qu'indicateur de la stérilité de la femme et de la réactivité au traitement
|
AU2010328336B2
(en)
|
2009-12-07 |
2017-03-02 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
EP2862929B1
(fr)
|
2009-12-09 |
2017-09-06 |
Quark Pharmaceuticals, Inc. |
Compositions et procédés pour le traitement de maladies, troubles ou lésions du système nerveux central
|
WO2011072082A2
(fr)
|
2009-12-09 |
2011-06-16 |
Nitto Denko Corporation |
Modulation de l'expression de hsp47
|
US10640457B2
(en)
|
2009-12-10 |
2020-05-05 |
The Trustees Of Columbia University In The City Of New York |
Histone acetyltransferase activators and uses thereof
|
JP6093180B2
(ja)
|
2009-12-10 |
2017-03-08 |
トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク |
ヒストンアセチルトランスフェラーゼ活性化剤及びその使用
|
NZ600725A
(en)
|
2009-12-18 |
2015-08-28 |
Univ British Colombia |
Methods and compositions for delivery of nucleic acids
|
CN105125572A
(zh)
|
2009-12-18 |
2015-12-09 |
箭头研究公司 |
用于治疗hsf1相关疾病的有机组合物
|
EP3721943A1
(fr)
|
2009-12-23 |
2020-10-14 |
Novartis AG |
Lipides, compositions de lipides et leurs procédés d'utilisation
|
WO2011084193A1
(fr)
|
2010-01-07 |
2011-07-14 |
Quark Pharmaceuticals, Inc. |
Composés oligonucléotidique comportant des extrémités sortantes non nucléotidiques
|
EP2529033B1
(fr)
|
2010-01-26 |
2017-05-24 |
National Jewish Health |
Procédés pour la prédiction des risques, le diagnostic, le pronostic de troubles pulmonaires
|
WO2011094580A2
(fr)
|
2010-01-28 |
2011-08-04 |
Alnylam Pharmaceuticals, Inc. |
Cuivre chélaté à utiliser dans la préparation d'oligonucléotides conjugués
|
US9198972B2
(en)
|
2010-01-28 |
2015-12-01 |
Alnylam Pharmaceuticals, Inc. |
Monomers and oligonucleotides comprising cycloaddition adduct(s)
|
MX2012009318A
(es)
|
2010-02-10 |
2012-09-07 |
Novartis Ag |
Metodos y compuestos para el crecimiento muscular.
|
RU2615143C2
(ru)
|
2010-03-24 |
2017-04-04 |
Адвирна |
Самодоставляющие PHKi соединения уменьшенного размера
|
CN103108642B
(zh)
|
2010-03-24 |
2015-09-23 |
雷克西制药公司 |
皮肤与纤维化症候中的rna干扰
|
WO2011119871A1
(fr)
|
2010-03-24 |
2011-09-29 |
Rxi Phrmaceuticals Corporation |
Arn interférant dans des indications oculaires
|
WO2011120953A1
(fr)
|
2010-03-29 |
2011-10-06 |
Universite De Strasbourg |
Polymères pour l'administration de molécules d'intérêt
|
CA2792291A1
(fr)
|
2010-03-29 |
2011-10-06 |
Kumamoto University |
Therapie siarn pour amylose oculaire liee a la transthyretine (ttr)
|
WO2011123621A2
(fr)
|
2010-04-01 |
2011-10-06 |
Alnylam Pharmaceuticals Inc. |
Monomères modifiés en 2' et 5' et oligonucléotides
|
EP3578657B1
(fr)
|
2010-04-06 |
2024-03-20 |
Alnylam Pharmaceuticals, Inc. |
Compositions et procédés d'inhibition de l'expression du gène cd274/pd-l1
|
WO2011133931A1
(fr)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Utilisation d'antagonistes d'il-27 pour traiter une maladie intestinale inflammatoire
|
US20130260460A1
(en)
|
2010-04-22 |
2013-10-03 |
Isis Pharmaceuticals Inc |
Conformationally restricted dinucleotide monomers and oligonucleotides
|
US10913767B2
(en)
|
2010-04-22 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
US9725479B2
(en)
|
2010-04-22 |
2017-08-08 |
Ionis Pharmaceuticals, Inc. |
5′-end derivatives
|
ES2574204T3
(es)
|
2010-04-23 |
2016-06-15 |
Arrowhead Research Corporation |
Composiciones orgánicas para tratar enfermedades relacionadas con beta-ENaC
|
KR101223660B1
(ko)
|
2010-05-20 |
2013-01-17 |
광주과학기술원 |
HIF-2α 억제제를 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물
|
WO2011146938A1
(fr)
|
2010-05-21 |
2011-11-24 |
NanoOncology, Inc. |
Réactifs et méthodes pour le traitement du cancer
|
KR20130108984A
(ko)
|
2010-05-26 |
2013-10-07 |
셀렉타 바이오사이언시즈, 인크. |
합성 나노담체 조합 백신
|
US20130149320A1
(en)
|
2010-05-31 |
2013-06-13 |
Centre National De La Recherche Scientifique |
Asf1b as a Prognosis Marker and Therapeutic Target in Human Cancer
|
EP2576579B1
(fr)
|
2010-06-02 |
2018-08-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions et méthodes pour traiter une fibrose hépatique
|
US20130236968A1
(en)
|
2010-06-21 |
2013-09-12 |
Alnylam Pharmaceuticals, Inc. |
Multifunctional copolymers for nucleic acid delivery
|
WO2011163466A1
(fr)
|
2010-06-23 |
2011-12-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Régulation de la pigmentation cutanée par la neuroréguline-1 (nrg-1)
|
WO2012016184A2
(fr)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Procédés et compositions pour la délivrance d'agents actifs
|
US20130202652A1
(en)
|
2010-07-30 |
2013-08-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
EP3330377A1
(fr)
|
2010-08-02 |
2018-06-06 |
Sirna Therapeutics, Inc. |
Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian)
|
CN103282497B
(zh)
|
2010-08-17 |
2018-07-10 |
瑟纳治疗公司 |
使用短干扰核酸(siNA)的乙型肝炎病毒(HBV)基因表达的RNA干扰介导的抑制
|
CN103140582A
(zh)
|
2010-08-24 |
2013-06-05 |
默沙东公司 |
含有内部非核酸间隔子的单链RNAi试剂
|
WO2012027467A1
(fr)
|
2010-08-26 |
2012-03-01 |
Merck Sharp & Dohme Corp. |
Inhibition médiée par interférence arn de l'expression du gène phd2 (prolyl hydroxylase domaine 2) utilisant un petit acide nucléique interférent (pani)
|
EP2433644A1
(fr)
|
2010-09-22 |
2012-03-28 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Traitement du cancer du sein
|
US20140134231A1
(en)
|
2010-10-11 |
2014-05-15 |
Sanford-Burnham Medical Research Institute |
Mir-211 expression and related pathways in human melanoma
|
AR083445A1
(es)
|
2010-10-14 |
2013-02-27 |
Univ Mie |
siARN CONTRA LA FIBROSIS
|
WO2012051567A2
(fr)
|
2010-10-15 |
2012-04-19 |
The Trustees Of Columbia University In The City Of New York |
Gènes de l'obésité, leurs protéines et leurs utilisations
|
DK2632472T3
(en)
|
2010-10-29 |
2018-03-19 |
Sirna Therapeutics Inc |
RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
|
CA2816584A1
(fr)
|
2010-11-01 |
2012-05-10 |
Peptimed, Inc. |
Compositions d'un systeme a base de peptides pour le ciblage specifique de cellules
|
US9198911B2
(en)
|
2010-11-02 |
2015-12-01 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating hair loss disorders
|
DK2635299T3
(da)
|
2010-11-02 |
2019-10-21 |
Univ Columbia |
Fremgangsmåder til behandling af hårtabsforstyrrelser
|
WO2012064824A1
(fr)
|
2010-11-09 |
2012-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions à formulation lipidique et procédés d'inhibition de l'expression des gènes eg5 et vegf
|
EP2455456A1
(fr)
|
2010-11-22 |
2012-05-23 |
Institut Curie |
Utilisation d'inhibiteurs de kinésine pour le traitement de l'infection du VIH et leur procédé de criblage
|
US9150926B2
(en)
|
2010-12-06 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Diagnosis and treatment of adrenocortical tumors using human microRNA-483
|
CA2818024C
(fr)
|
2010-12-06 |
2019-09-24 |
Quark Pharmaceuticals, Inc. |
Composes oligonucleotidiques a double brin comprenant des modifications de position
|
WO2012102793A2
(fr)
|
2010-12-10 |
2012-08-02 |
Zirus, Inc. |
Gènes de mammifère impliqués dans la toxicité et l'infection
|
EP3323813B1
(fr)
|
2010-12-22 |
2020-08-26 |
The Trustees of Columbia University in the City of New York |
Modulateurs de l'histone acétyltransférase et leurs utilisations
|
WO2012090150A2
(fr)
|
2010-12-27 |
2012-07-05 |
Compugen Ltd |
Nouveaux peptides pénétrant dans les cellules et leurs utilisations
|
JP5902197B2
(ja)
|
2011-01-11 |
2016-04-13 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
Peg化脂質および薬剤送達のためのそれらの使用
|
WO2012118911A1
(fr)
|
2011-03-03 |
2012-09-07 |
Quark Pharmaceuticals, Inc. |
Modulateurs des oligonucléotides de la voie de signalisation activée par les récepteurs de type toll
|
US9796979B2
(en)
|
2011-03-03 |
2017-10-24 |
Quark Pharmaceuticals Inc. |
Oligonucleotide modulators of the toll-like receptor pathway
|
KR101937498B1
(ko)
|
2011-03-03 |
2019-04-10 |
쿠아크 파마수티칼스 인코퍼레이티드 |
폐 질환 및 손상을 치료하기 위한 조성물 및 방법
|
WO2012119764A1
(fr)
|
2011-03-08 |
2012-09-13 |
Società Bulloneria Europea S.B.E. Spa |
Élément de fixation bridé à charge élevée destiné à être installé à l'aide d'outils de tension
|
CA2830403A1
(fr)
|
2011-03-15 |
2012-09-20 |
University Of Utah Research Foundation |
Procedes de diagnostic et de traitement de la maculopathie vasculaire associee et des symptomes correspondants
|
KR101291668B1
(ko)
|
2011-04-21 |
2013-08-01 |
서울대학교산학협력단 |
미코박테리아―대장균용 셔틀 벡터 및 이의 용도
|
TWI658830B
(zh)
|
2011-06-08 |
2019-05-11 |
日東電工股份有限公司 |
Hsp47表現調控強化用類視色素脂質體
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
EP3388068A1
(fr)
|
2011-06-21 |
2018-10-17 |
Alnylam Pharmaceuticals, Inc. |
Composition et procédés d'inhibition de l'expression des gènes de la protéine c (proc)
|
WO2012177906A1
(fr)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Dosages et procédés de détermination de l'activité d'un agent thérapeutique chez un sujet
|
MX344807B
(es)
|
2011-06-21 |
2017-01-09 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibicion de genes para alipoproteina c-iii (apoc3).
|
US9228188B2
(en)
|
2011-06-21 |
2016-01-05 |
Alnylam Pharmaceuticals, Inc. |
Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression
|
EP2723390B1
(fr)
|
2011-06-23 |
2017-12-27 |
Alnylam Pharmaceuticals, Inc. |
Arnsi de serpina1 : compositions et méthodes de traitement
|
WO2013003697A1
(fr)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Méthode de régulation de croissance tumorale, d'angiogenèse et de métastase à l'aide du récepteur 1 riche en proline et contenant une immunoglobuline (igpr-1)
|
CN103930165B
(zh)
|
2011-09-02 |
2018-05-25 |
纽约市哥伦比亚大学理事会 |
用以治疗肥胖症的代谢紊乱的CaMKII、IP3R、钙调神经磷酸酶、P38和MK2/3抑制剂
|
US20160032284A1
(en)
|
2011-09-02 |
2016-02-04 |
Arrowhead Research Corportation |
Organic compositions to treat hsf1-related diseases
|
US9644241B2
(en)
|
2011-09-13 |
2017-05-09 |
Interpace Diagnostics, Llc |
Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
|
US9352312B2
(en)
|
2011-09-23 |
2016-05-31 |
Alere Switzerland Gmbh |
System and apparatus for reactions
|
AU2012315965A1
(en)
|
2011-09-27 |
2014-04-03 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted PEGylated lipids
|
CA2850032C
(fr)
|
2011-10-14 |
2022-06-07 |
Genentech, Inc. |
Anticorps anti-htra1 et leurs procedes d'utilisation
|
EP2768958B1
(fr)
|
2011-10-18 |
2019-08-14 |
Dicerna Pharmaceuticals, Inc. |
Lipides cationiques aminés et utilisations associées
|
SG11201401648RA
(en)
|
2011-11-03 |
2014-05-29 |
Quark Pharmaceuticals Inc |
Methods and compositions for neuroprotection
|
WO2013070821A1
(fr)
|
2011-11-08 |
2013-05-16 |
Quark Pharmaceuticals, Inc. |
Méthodes et compositions destinées à traiter des maladies, des troubles ou une lésion du système nerveux
|
CA2860676A1
(fr)
|
2012-01-09 |
2013-07-18 |
Novartis Ag |
Compositions organiques pour traiter des maladies associees a la beta-catenine
|
KR101371696B1
(ko)
|
2012-02-02 |
2014-03-07 |
세종대학교산학협력단 |
벼도열병 발병인자의 스크리닝 방법
|
EP2812012A1
(fr)
|
2012-02-07 |
2014-12-17 |
Global Bio Therapeutics USA, Inc. |
Procédé compartimenté d'administration d'acide nucléique et ses compositions et utilisations
|
KR102135601B1
(ko)
|
2012-03-29 |
2020-07-20 |
더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 |
탈모 질환의 치료 방법
|
EP2844261B1
(fr)
|
2012-05-02 |
2018-10-17 |
Sirna Therapeutics, Inc. |
Compositions de petit acide nucléique interférent (sina)
|
EA201492004A1
(ru)
|
2012-05-02 |
2015-08-31 |
Новартис Аг |
Органические композиции для лечения kras-ассоциированных заболеваний
|
WO2013170960A1
(fr)
|
2012-05-16 |
2013-11-21 |
Silence Therapeutics Ag |
Utilisation de vegfr1 en tant que biomarqueur pour l'administration d'un inhibiteur de pkn3
|
WO2013187556A1
(fr)
|
2012-06-14 |
2013-12-19 |
Scripps Korea Antibody Institute |
Nouvel anticorps spécifique de clec14a et ses utilisations
|
WO2014006227A1
(fr)
|
2012-07-06 |
2014-01-09 |
Institut Gustave-Roussy |
Détection simultanée de cannibalisme et de sénescence à titre de marqueur pronostique du cancer
|
WO2014018554A1
(fr)
|
2012-07-23 |
2014-01-30 |
La Jolla Institute For Allergy And Immunology |
Ptprs et protéoglycanes dans une maladie auto-immune
|
WO2014018375A1
(fr)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 et ses utilisations dans des méthodes thérapeutiques et diagnostiques
|
EP2700949A1
(fr)
|
2012-08-24 |
2014-02-26 |
IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. |
Utilisation de protéines de la biliverdine réductase comme marqueur de cancer
|
ES2776029T3
(es)
|
2012-10-08 |
2020-07-28 |
St Jude Childrens Res Hospital |
Terapias basadas en el control de la estabilidad y función de las células T reguladoras por medio de un eje neuropilina-1:semaforina
|
WO2014068072A1
(fr)
|
2012-10-31 |
2014-05-08 |
Institut Gustave-Roussy |
Identification, évaluation et traitement de la thrombocytémie essentielle associée à une résistance aux inhibiteurs de jak2
|
SG10201706960TA
(en)
|
2013-02-28 |
2017-10-30 |
Arrowhead Res Corp |
Organic compositions to treat epas1-related diseases
|
WO2014135655A1
(fr)
|
2013-03-06 |
2014-09-12 |
Institut Curie |
Compositions et méthodes de traitement du cancer de la vessie invasif pour le muscle
|
JP6352950B2
(ja)
|
2013-03-08 |
2018-07-04 |
ノバルティス アーゲー |
活性薬物の送達のための脂質と脂質組成物
|
BR112015023108A8
(pt)
|
2013-03-13 |
2018-01-23 |
Geneweave Biosciences Inc |
sistema de acondicionamento de célula bacteriana, método para acondicionamento de uma molécula de ácido nucléico repórter, composição, método para detectar uma presença ou uma ausência de uma célula bacteriana em uma amostra, vetor, método para detectar um transcrito alvo em uma célula, método para detectar a presença de uma célula bacteriana em uma amostra e kit.
|
AU2014233198B2
(en)
|
2013-03-15 |
2019-06-27 |
Sutter West Bay Hospitals |
Falz for use as a target for therapies to treat cancer
|
WO2014151734A1
(fr)
|
2013-03-15 |
2014-09-25 |
The Trustees Of Columbia University In The City Of New York |
Protéines de fusion et procédés correspondants
|
US9937231B2
(en)
|
2013-03-27 |
2018-04-10 |
The General Hospital Corporation |
Methods and agents for treating Alzheimer's disease
|
JP6896420B2
(ja)
|
2013-07-03 |
2021-06-30 |
シティ・オブ・ホープCity of Hope |
抗癌組成物
|
EP3019609B8
(fr)
|
2013-07-10 |
2018-07-18 |
Basf Se |
Arni inhibant l'expression des gènes cyp51 pouvant être utilisés en vue de la lutte contre les champignons et les oomycètes phytopathogènes
|
RU2703498C2
(ru)
|
2013-07-19 |
2019-10-17 |
Монсанто Текнолоджи Ллс |
Композиции и способы борьбы с leptinotarsa
|
WO2015015498A1
(fr)
|
2013-07-31 |
2015-02-05 |
Qbi Enterprises Ltd. |
Procédés d'utilisation de composés sphingolipide-polyalkylamine-oligonucléotide
|
US9889200B2
(en)
|
2013-07-31 |
2018-02-13 |
Qbi Enterprises Ltd. |
Sphingolipid-polyalkylamine-oligonucleotide compounds
|
MX366880B
(es)
|
2013-08-08 |
2019-07-29 |
Global Bio Therapeutics Inc |
Dispositivo de inyección para procedimientos mínimamente invasivos y usos del mismo.
|
DK3030163T3
(da)
|
2013-08-08 |
2019-07-01 |
Global Bio Therapeutics Inc |
Klemmeindretning til minimalt invasive procedurer
|
JP6546161B2
(ja)
|
2013-10-04 |
2019-07-17 |
ノバルティス アーゲー |
B型肝炎ウイルスを治療するための有機化合物
|
WO2015051044A2
(fr)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Formats inédits pour composés organiques utiisables en interférence arn
|
WO2015051366A2
(fr)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Formats inédits pour composés organiques utilisables en interférence arn
|
JP6694811B2
(ja)
|
2013-10-04 |
2020-05-20 |
ノバルティス アーゲー |
RNA干渉に使用するためのRNAi剤用の3’末端キャップ
|
WO2015051135A2
(fr)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Compositions organiques destinées au traitement de maladies associées à l'hepcidine
|
WO2015054451A1
(fr)
|
2013-10-09 |
2015-04-16 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services |
Détection du virus de l'hépatite delta (vhd) pour le diagnostic et le traitement du syndrome de sjögren et du lymphome
|
KR20160068855A
(ko)
|
2013-10-11 |
2016-06-15 |
제넨테크, 인크. |
Nsp4 억제제 및 사용 방법
|
CA2929574A1
(fr)
|
2013-11-11 |
2015-05-14 |
Sirna Therapeutics, Inc. |
Administration systemique de petits acides nucleiques interferents ciblant la myostatine conjugues a une fraction lipophile
|
EP3079707A4
(fr)
|
2013-12-02 |
2017-10-18 |
RXi Pharmaceuticals Corporation |
Immunothérapie du cancer
|
ES2908827T3
(es)
|
2013-12-19 |
2022-05-04 |
Novartis Ag |
Lípidos y composiciones lipídicas para el suministro de agentes activos
|
EP3872066A1
(fr)
|
2013-12-19 |
2021-09-01 |
Novartis AG |
Lipides et compositions lipidiques pour l'administration d'agents actifs
|
US9682123B2
(en)
|
2013-12-20 |
2017-06-20 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating metabolic disease
|
US9274117B2
(en)
|
2013-12-21 |
2016-03-01 |
Catholic University Industry Academic |
Use of SIRT7 as novel cancer therapy target and method for treating cancer using the same
|
EP3088001B1
(fr)
|
2013-12-27 |
2020-02-12 |
National University Corporation Kochi University |
Anticorps anti-lipolysis stimulated liporotein receptor pour le traitement du cancer de l'ovaire
|
WO2015118167A1
(fr)
|
2014-02-10 |
2015-08-13 |
Institut Curie |
Utilisation de modulateurs de mcoln-1 pour réguler la migration cellulaire
|
EP3693384B1
(fr)
|
2014-03-11 |
2024-01-24 |
Cellectis |
Procédé d'obtention de lymphocytes t compatibles avec la transplantation allogénique
|
CN106460025A
(zh)
|
2014-03-25 |
2017-02-22 |
阿克丘勒斯治疗公司 |
在基因沉默中具有降低的脱靶效应的una寡聚物
|
US9856475B2
(en)
|
2014-03-25 |
2018-01-02 |
Arcturus Therapeutics, Inc. |
Formulations for treating amyloidosis
|
WO2015148582A1
(fr)
|
2014-03-25 |
2015-10-01 |
Arcturus Therapeutics, Inc. |
Oligomères d'una sélectifs d'allèle de transthyrétine, pour inactivation génique
|
EP3125936B1
(fr)
|
2014-03-31 |
2019-05-08 |
Debiopharm International SA |
Fusions de fgfr
|
CN110506752B
(zh)
|
2014-04-01 |
2022-02-18 |
孟山都技术公司 |
用于控制虫害的组合物和方法
|
US11279934B2
(en)
|
2014-04-28 |
2022-03-22 |
Phio Pharmaceuticals Corp. |
Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
|
KR101633876B1
(ko)
|
2014-05-08 |
2016-06-28 |
고려대학교 산학협력단 |
정서장애 및 중독질환 치료를 위한 REV-ERBα 유전자의 용도
|
KR101633881B1
(ko)
|
2014-05-08 |
2016-06-28 |
고려대학교 산학협력단 |
도파민 의존성 신경장애 치료를 위한 REV-ERBα 유전자의 용도
|
JP6778175B2
(ja)
|
2014-07-16 |
2020-10-28 |
ノバルティス アーゲー |
脂質ナノ粒子ホスト中に核酸を封入する方法
|
WO2016011123A1
(fr)
|
2014-07-16 |
2016-01-21 |
Arrowhead Research Corporation |
Compositions organiques pour letraitement de pathologies liées à l'apoc3
|
UA125244C2
(uk)
|
2014-07-29 |
2022-02-09 |
Монсанто Текнолоджі Елелсі |
Спосіб умертвіння або припинення росту комахи
|
US11466061B2
(en)
|
2014-08-22 |
2022-10-11 |
Yingfang Liu |
Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the IFP35 family of proteins
|
EP3188799B1
(fr)
|
2014-09-05 |
2022-07-06 |
Phio Pharmaceuticals Corp. |
Méthodes de traitement de troubles cutanés et du vieillissement à l'aide d'acides nucléiques ciblant tyr ou mmp1
|
CN107072946B
(zh)
|
2014-09-05 |
2022-01-11 |
诺华股份有限公司 |
用于递送活性剂的脂质和脂质组合物
|
EP3194581A4
(fr)
|
2014-09-15 |
2018-04-25 |
Children's Medical Center Corporation |
Méthodes et compositions pour augmenter l'efficacité du transfert nucléaire des cellules somatiques (scnt) par élimination de la triméthylation de la lysine de l'histone h3
|
AU2015320748A1
(en)
|
2014-09-25 |
2017-04-20 |
Cold Spring Harbor Laboratory |
Treatment of Rett Syndrome
|
WO2016057693A1
(fr)
|
2014-10-10 |
2016-04-14 |
Alnylam Pharmaceuticals, Inc. |
Procédés et compositions pour administration par inhalation d'oligonucléotide conjugué
|
UA124449C2
(uk)
|
2014-11-12 |
2021-09-22 |
Нмк, Інк. |
Трансгенна рослина з модифікованою редокс-залежною модуляцією пігментів фотосинтетичних антенних комплексів та спосіб її одержання
|
EP3925979A3
(fr)
|
2014-12-23 |
2022-03-23 |
The Trustees of Columbia University in the City of New York |
Protéines de fusion fgfr-tacc et utilisations associées
|
US10264976B2
(en)
|
2014-12-26 |
2019-04-23 |
The University Of Akron |
Biocompatible flavonoid compounds for organelle and cell imaging
|
US10968449B2
(en)
|
2015-01-22 |
2021-04-06 |
Monsanto Technology Llc |
Compositions and methods for controlling Leptinotarsa
|
AU2016226414B2
(en)
|
2015-03-02 |
2021-09-09 |
180 Therapeutics Lp |
Method of treating a localized fibrotic disorder using an IL-33 antagonist
|
WO2016145003A1
(fr)
|
2015-03-09 |
2016-09-15 |
University Of Kentucky Research Foundation |
Nanoparticules d'arn pour le traitement du cancer gastrique
|
US11085044B2
(en)
|
2015-03-09 |
2021-08-10 |
University Of Kentucky Research Foundation |
miRNA for treatment of breast cancer
|
CN111961103B
(zh)
|
2015-03-09 |
2023-06-16 |
肯塔基大学研究基金会 |
用于脑肿瘤治疗的rna纳米颗粒
|
KR101797569B1
(ko)
|
2015-03-18 |
2017-11-22 |
한국교통대학교산학협력단 |
금속 나노입자 기반 간 표적성 핵산 전달체 및 이의 제조방법
|
JP6830441B2
(ja)
|
2015-04-01 |
2021-02-17 |
アークトゥラス・セラピューティクス・インコーポレイテッドArcturus Therapeutics,Inc. |
治療上のunaオリゴマーおよびその使用
|
US11279768B1
(en)
|
2015-04-03 |
2022-03-22 |
Precision Biologics, Inc. |
Anti-cancer antibodies, combination therapies, and uses thereof
|
US10828381B2
(en)
|
2015-04-17 |
2020-11-10 |
University Of Kentucky Research Foundation |
RNA nanoparticles and method of use thereof
|
US20180156807A1
(en)
|
2015-04-29 |
2018-06-07 |
New York University |
Method for treating high-grade gliomas
|
JP7497953B2
(ja)
|
2015-06-12 |
2024-06-11 |
アレクトル エルエルシー |
抗cd33抗体及びその使用方法
|
AU2016276981B2
(en)
|
2015-06-12 |
2022-10-06 |
Alector Llc |
Anti-CD33 antibodies and methods of use thereof
|
EP3313420B1
(fr)
|
2015-06-25 |
2024-03-13 |
The Children's Medical Center Corporation |
Procédés et compositions se rapportant à l'expansion, l'enrichissement et la conservation de cellules souches hématopoïétiques
|
JP6983752B2
(ja)
|
2015-07-06 |
2021-12-17 |
フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. |
スーパーオキシドディスムターゼ1(sod1)を標的とする核酸分子
|
WO2017007825A1
(fr)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Procédés pour le traitement de troubles neurologiques à l'aide d'une petite molécule synergique et approche thérapeutique utilisant des acides nucléiques
|
WO2017015671A1
(fr)
|
2015-07-23 |
2017-01-26 |
Arcturus Therapeutics, Inc. |
Compositions permettant de traiter l'amylose
|
WO2017013270A1
(fr)
|
2015-07-23 |
2017-01-26 |
Universite De Strasbourg |
Utilisation d'un inhibiteur de la signalisation de la leptine pour la protection des reins de patients atteints de ciliopathie
|
JP2018525037A
(ja)
|
2015-08-24 |
2018-09-06 |
ハロー−バイオ・アールエヌエーアイ・セラピューティックス、インコーポレイテッド |
遺伝子発現の調節のためのポリヌクレオチドナノ粒子及びその使用
|
US10072065B2
(en)
|
2015-08-24 |
2018-09-11 |
Mayo Foundation For Medical Education And Research |
Peptide-mediated delivery of immunoglobulins across the blood-brain barrier
|
WO2017040301A1
(fr)
|
2015-08-28 |
2017-03-09 |
Alector Llc |
Anticorps anti-siglec-7 et leurs méthodes d'utilisation
|
WO2017040078A1
(fr)
|
2015-09-02 |
2017-03-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni ciblant le ligand de mort cellulaire programmée 1 (pd-l1) et leurs méthodes d'utilisation
|
EP3702470A3
(fr)
|
2015-09-09 |
2020-10-07 |
The Trustees of Columbia University in the City of New York |
Réduction du fragment c99 de l'app localisé sur la membrane er-mam et procédés de traitement de la maladie d'alzheimer
|
WO2017058944A1
(fr)
|
2015-09-29 |
2017-04-06 |
Amgen Inc. |
Inhibiteurs de l'asgr pour réduire les taux de cholestérol
|
WO2017059113A1
(fr)
|
2015-09-29 |
2017-04-06 |
Duke University |
Compositions et méthodes pour identifier et traiter des troubles associés à la dystonie
|
JP2018531037A
(ja)
|
2015-10-19 |
2018-10-25 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
長い非コードrnaを標的とする減少したサイズの自己送達型核酸化合物
|
WO2017075432A2
(fr)
|
2015-10-29 |
2017-05-04 |
Alector Llc |
Anticorps anti-siglec-9 et leurs procédés d'utilisation
|
BR112018007703A2
(pt)
|
2015-10-30 |
2018-11-06 |
Genentech Inc |
anticorpos, ácido nucleico isolado, métodos de produção de um anticorpo e de tratamento de um distúrbio, composição farmacêutica, terapia de combinação e uso do anticorpo
|
KR20180086260A
(ko)
|
2015-12-13 |
2018-07-30 |
닛토덴코 가부시키가이샤 |
높은 활성 및 감소한 오프 타겟을 위한 sirna 구조
|
EP3423568A4
(fr)
|
2016-03-04 |
2019-11-13 |
University Of Louisville Research Foundation, Inc. |
Procédés et compositions pour l'expansion ex vivo de très petites cellules souches de type embryonnaire (vsel)
|
EP3429603B1
(fr)
|
2016-03-15 |
2021-12-29 |
Children's Medical Center Corporation |
Procédés et compositions concernant l'expansion de cellules souches hématopoïétiques
|
WO2017173327A1
(fr)
|
2016-03-31 |
2017-10-05 |
The Schepens Eye Research Institute, Inc. |
Inhibiteur de l'endomucine utilisé comme agent anti-angiogénique
|
MA45469A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques de bêta-caténine et leurs utilisations
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
MA45470A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques kras et leurs utilisations
|
MA45349A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques egfr et leurs utilisations
|
FI3445773T3
(fi)
|
2016-05-13 |
2023-03-30 |
4D Molecular Therapeutics Inc |
Adenoassosioituneen viruksen kapsidimuunnoksia ja niiden käyttömenetelmiä
|
EP3519582A1
(fr)
|
2016-07-29 |
2019-08-07 |
Danmarks Tekniske Universitet |
Procédés de découplage de la croissance de cellules à partir de la production de produits biochimiques et de polypeptides recombinants
|
EP3516062A1
(fr)
|
2016-09-21 |
2019-07-31 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni de myostatine et procédés d'utilisation associés
|
CA3043768A1
(fr)
|
2016-11-29 |
2018-06-07 |
PureTech Health LLC |
Exosomes destines a l'administration d'agents therapeutiques
|
US11147249B2
(en)
|
2016-12-08 |
2021-10-19 |
Alector Llc |
Siglec transgenic mice and methods of use thereof
|
JP7141397B2
(ja)
|
2016-12-16 |
2022-09-22 |
ユニヴェルシテ・ドゥ・ボルドー |
Mmp9インヒビター及び色素脱失障害の予防又は処置におけるその使用
|
US11359014B2
(en)
|
2017-05-16 |
2022-06-14 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
KR20200015943A
(ko)
|
2017-06-15 |
2020-02-13 |
캔설 어드밴스 아이엔씨 |
종양 및 암에 대한 체액성 및 세포 면역을 유도하기 위한 조성물 및 방법
|
AU2018285579A1
(en)
|
2017-06-16 |
2019-12-12 |
Imba - Institut Für Molekulare Biotechnologie Gmbh |
Blood vessel organoid, methods of producing and using said organoids
|
CN117700548A
(zh)
|
2017-08-03 |
2024-03-15 |
艾利妥 |
抗cd33抗体及其使用方法
|
WO2019047914A1
(fr)
|
2017-09-07 |
2019-03-14 |
北京泰德制药股份有限公司 |
Molécule d'arn double brin ciblant ckip-1 et son utilisation
|
JOP20200054A1
(ar)
|
2017-09-11 |
2020-03-10 |
Arrowhead Pharmaceuticals Inc |
عوامل RNAi وتركيبات لتثبيط تعبير صَميمُ البروتينِ الشَّحْمِيّ C-III (APOC3)
|
PE20201264A1
(es)
|
2017-09-20 |
2020-11-19 |
4D Molecular Therapeutics Inc |
Variantes de capsides de virus adenoasociados y metodos de uso de estas
|
UA127831C2
(uk)
|
2017-11-27 |
2024-01-17 |
4Д Молекьюлар Терапьютикс Інк. |
Капсид аденоасоційованого вірусу та його застосування для інгібування ангіогенезу
|
AU2018378812A1
(en)
|
2017-12-06 |
2020-07-09 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle atrophy and myotonic dystrophy
|
US11470827B2
(en)
|
2017-12-12 |
2022-10-18 |
Alector Llc |
Transgenic mice expressing human TREM proteins and methods of use thereof
|
US11597932B2
(en)
|
2017-12-21 |
2023-03-07 |
Alnylam Pharmaceuticals, Inc. |
Chirally-enriched double-stranded RNA agents
|
US20210162007A1
(en)
|
2018-04-09 |
2021-06-03 |
President And Fellows Of Harvard College |
Modulating nuclear receptors and methods of using same
|
AU2019275071B2
(en)
|
2018-05-24 |
2022-12-15 |
Sirnaomics, Inc. |
Composition and methods of controllable co-coupling polypeptide nanoparticle delivery system for nucleic acid therapeutics
|
MX2021000933A
(es)
|
2018-07-27 |
2021-05-27 |
Alector Llc |
Anticuerpos anti-siglec-5 y métodos para su uso.
|
CN113015746A
(zh)
|
2018-09-19 |
2021-06-22 |
拉荷亚免疫研究所 |
在类风湿性关节炎中的ptprs和蛋白聚糖
|
TWI840449B
(zh)
|
2018-11-16 |
2024-05-01 |
日商日東電工股份有限公司 |
用於惡性腫瘤之rna干擾輸送配方及方法
|
US20220290156A1
(en)
|
2019-08-27 |
2022-09-15 |
Sanofi |
Compositions and methods for inhibiting pcsk9
|
KR102100163B1
(ko)
|
2019-09-24 |
2020-04-13 |
테고사이언스 (주) |
켈로이드 또는 비후성 반흔 예방 또는 치료용 조성물
|
JP2023506842A
(ja)
|
2019-12-18 |
2023-02-20 |
ノバルティス アーゲー |
異常ヘモグロビン症の治療用組成物及び方法
|
BR112022011796A2
(pt)
|
2019-12-18 |
2022-08-30 |
Novartis Ag |
Derivados de 3-(5-metóxi-1- oxoisoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
|
WO2021142191A1
(fr)
|
2020-01-08 |
2021-07-15 |
Regeneron Pharmaceuticals, Inc. |
Traitement de la fibrodysplasie ossifiante progressive
|
US20210222128A1
(en)
|
2020-01-22 |
2021-07-22 |
Massachusetts Institute Of Technology |
Inducible tissue constructs and uses thereof
|
WO2021173965A1
(fr)
|
2020-02-28 |
2021-09-02 |
Massachusetts Institute Of Technology |
Identification de résidus de grippe variables et leurs utilisations
|
TW202144572A
(zh)
|
2020-03-19 |
2021-12-01 |
美商亞維代堤生物科學公司 |
治療臉肩胛肱骨肌肉失養症之組合物及方法
|
WO2022147481A1
(fr)
|
2020-12-30 |
2022-07-07 |
Ansun Biopharma Inc. |
Polythérapie d'un virus oncolytique délivrant un antigène étranger et cellule immunitaire modifiée exprimant un récepteur chimérique ciblant l'antigène étranger
|
JP2024519888A
(ja)
|
2021-05-28 |
2024-05-21 |
上海瑞宏迪医薬有限公司 |
カプシド変異を有する組換えアデノ随伴ウイルス及びその応用
|
WO2022269518A2
(fr)
|
2021-06-23 |
2022-12-29 |
Novartis Ag |
Compositions et méthodes pour le traitement d'hémoglobinopathies
|
EP4381069A1
(fr)
|
2021-08-02 |
2024-06-12 |
Universite De Montpellier |
Compositions et méthodes de traitement des maladies cmt1a ou cmt1e avec des molécules d'arni ciblant pmp22
|
WO2023064928A2
(fr)
|
2021-10-14 |
2023-04-20 |
Arsenal Biosciences, Inc. |
Cellules immunitaires ayant des arnsh co-exprimés et des systèmes de porte logique
|
TW202417626A
(zh)
|
2022-09-13 |
2024-05-01 |
美商亞森諾生物科學公司 |
具有共表現的tgfbr shrna之免疫細胞
|
WO2024059824A2
(fr)
|
2022-09-16 |
2024-03-21 |
Arsenal Biosciences, Inc. |
Cellules immunitaires à perturbations géniques combinées
|